00014024792023Q2FALSE--12-310.020.020.020.03330.01250.02000.0200http://medavail.com/20230630#LeaseRightOfUseAssethttp://medavail.com/20230630#LeaseRightOfUseAssethttp://medavail.com/20230630#LeaseRightOfUseAssethttp://medavail.com/20230630#LeaseRightOfUseAssethttp://medavail.com/20230630#LeaseLiabilityCurrenthttp://medavail.com/20230630#LeaseLiabilityCurrenthttp://medavail.com/20230630#LeaseLiabilityNoncurrenthttp://medavail.com/20230630#LeaseLiabilityNoncurrenthttp://medavail.com/20230630#LeaseLiabilityCurrenthttp://medavail.com/20230630#LeaseLiabilityCurrenthttp://medavail.com/20230630#LeaseLiabilityNoncurrenthttp://medavail.com/20230630#LeaseLiabilityNoncurrent0.020.02000.02000.02000.03330.01250.02000.020000014024792023-01-012023-06-3000014024792023-08-08xbrli:shares00014024792023-06-30iso4217:USD00014024792022-12-31iso4217:USDxbrli:shares0001402479us-gaap:SubsequentEventMember2023-07-312023-07-31xbrli:pure0001402479medavail:HardwareAndSubscriptionMember2023-04-012023-06-300001402479medavail:HardwareAndSubscriptionMember2022-04-012022-06-300001402479medavail:HardwareAndSubscriptionMember2023-01-012023-06-300001402479medavail:HardwareAndSubscriptionMember2022-01-012022-06-300001402479us-gaap:ServiceMember2023-04-012023-06-300001402479us-gaap:ServiceMember2022-04-012022-06-300001402479us-gaap:ServiceMember2023-01-012023-06-300001402479us-gaap:ServiceMember2022-01-012022-06-3000014024792023-04-012023-06-3000014024792022-04-012022-06-3000014024792022-01-012022-06-300001402479us-gaap:RetainedEarningsMember2023-04-012023-06-300001402479us-gaap:RetainedEarningsMember2022-04-012022-06-300001402479us-gaap:RetainedEarningsMember2023-01-012023-06-300001402479us-gaap:RetainedEarningsMember2022-01-012022-06-300001402479us-gaap:CommonStockMember2023-03-310001402479us-gaap:WarrantMember2023-03-310001402479us-gaap:AdditionalPaidInCapitalMember2023-03-310001402479us-gaap:RetainedEarningsMember2023-03-310001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100014024792023-03-310001402479us-gaap:WarrantMemberus-gaap:PrivatePlacementMember2023-04-012023-06-300001402479us-gaap:PrivatePlacementMember2023-04-012023-06-300001402479us-gaap:CommonStockMember2023-04-012023-06-300001402479us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001402479us-gaap:CommonStockMember2023-06-300001402479us-gaap:WarrantMember2023-06-300001402479us-gaap:AdditionalPaidInCapitalMember2023-06-300001402479us-gaap:RetainedEarningsMember2023-06-300001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001402479us-gaap:CommonStockMember2022-12-310001402479us-gaap:WarrantMember2022-12-310001402479us-gaap:AdditionalPaidInCapitalMember2022-12-310001402479us-gaap:RetainedEarningsMember2022-12-310001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001402479us-gaap:WarrantMemberus-gaap:PrivatePlacementMember2023-01-012023-06-300001402479us-gaap:PrivatePlacementMember2023-01-012023-06-300001402479us-gaap:CommonStockMember2023-01-012023-06-300001402479us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001402479us-gaap:CommonStockMember2022-03-310001402479us-gaap:WarrantMember2022-03-310001402479us-gaap:AdditionalPaidInCapitalMember2022-03-310001402479us-gaap:RetainedEarningsMember2022-03-310001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100014024792022-03-310001402479us-gaap:CommonStockMember2022-04-012022-06-300001402479us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001402479us-gaap:WarrantMember2022-04-012022-06-300001402479us-gaap:CommonStockMember2022-06-300001402479us-gaap:WarrantMember2022-06-300001402479us-gaap:AdditionalPaidInCapitalMember2022-06-300001402479us-gaap:RetainedEarningsMember2022-06-300001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000014024792022-06-300001402479us-gaap:CommonStockMember2021-12-310001402479us-gaap:WarrantMember2021-12-310001402479us-gaap:AdditionalPaidInCapitalMember2021-12-310001402479us-gaap:RetainedEarningsMember2021-12-310001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100014024792021-12-310001402479us-gaap:CommonStockMember2022-01-012022-06-300001402479us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001402479us-gaap:WarrantMember2022-01-012022-06-300001402479us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2022-01-012022-06-3000014024792023-01-182023-01-1800014024792023-02-092023-02-090001402479us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMembermedavail:PharmacyServicesBusinessMember2022-01-012022-12-310001402479medavail:InventoryFromSpotRxPharmaciesMember2022-12-310001402479medavail:InventoryFromSpotRxPharmaciesMemberus-gaap:ProductConcentrationRiskMemberus-gaap:AssetsTotalMember2022-01-012022-12-3100014024792023-06-140001402479srt:MinimumMember2023-06-142023-06-140001402479srt:MaximumMember2023-06-142023-06-140001402479us-gaap:SubsequentEventMember2023-07-142023-07-140001402479us-gaap:PrivatePlacementMember2023-03-092023-03-090001402479medavail:PreFundedWarrantMemberus-gaap:PrivatePlacementMember2023-03-130001402479medavail:SeriesAWarrantMemberus-gaap:PrivatePlacementMember2023-06-160001402479medavail:WarrantsIssuedNovember182020OutstandingMember2023-01-012023-06-300001402479medavail:WarrantsIssuedMarch92023OutstandingMember2023-01-012023-06-300001402479us-gaap:FairValueMeasurementsRecurringMember2022-12-310001402479us-gaap:FairValueMeasurementsRecurringMember2023-06-300001402479medavail:PreFundedWarrantMemberus-gaap:FairValueMeasurementsRecurringMembermedavail:WarrantLiabilityMember2023-03-130001402479medavail:SeriesAWarrantMemberus-gaap:FairValueMeasurementsRecurringMembermedavail:WarrantLiabilityMember2023-03-1300014024792023-03-132023-03-130001402479medavail:PreFundedWarrantMemberus-gaap:FairValueMeasurementsRecurringMembermedavail:WarrantLiabilityMember2023-03-142023-06-140001402479medavail:SeriesAWarrantMemberus-gaap:FairValueMeasurementsRecurringMembermedavail:WarrantLiabilityMember2023-03-142023-06-1400014024792023-03-142023-06-140001402479medavail:PreFundedWarrantMemberus-gaap:FairValueMeasurementsRecurringMembermedavail:WarrantLiabilityMember2023-06-140001402479medavail:SeriesAWarrantMemberus-gaap:FairValueMeasurementsRecurringMembermedavail:WarrantLiabilityMember2023-06-140001402479us-gaap:MachineryAndEquipmentMember2023-06-300001402479us-gaap:MachineryAndEquipmentMember2022-12-310001402479srt:MinimumMemberus-gaap:TechnologyEquipmentMember2023-06-300001402479srt:MaximumMemberus-gaap:TechnologyEquipmentMember2023-06-300001402479us-gaap:TechnologyEquipmentMember2023-06-300001402479us-gaap:TechnologyEquipmentMember2022-12-310001402479us-gaap:LeaseholdImprovementsMember2023-06-300001402479us-gaap:LeaseholdImprovementsMember2022-12-310001402479srt:MinimumMemberus-gaap:OtherMachineryAndEquipmentMember2023-06-300001402479srt:MaximumMemberus-gaap:OtherMachineryAndEquipmentMember2023-06-300001402479us-gaap:OtherMachineryAndEquipmentMember2023-06-300001402479us-gaap:OtherMachineryAndEquipmentMember2022-12-310001402479srt:MinimumMemberus-gaap:OfficeEquipmentMember2023-06-300001402479srt:MaximumMemberus-gaap:OfficeEquipmentMember2023-06-300001402479us-gaap:OfficeEquipmentMember2023-06-300001402479us-gaap:OfficeEquipmentMember2022-12-310001402479us-gaap:VehiclesMember2023-06-300001402479us-gaap:VehiclesMember2022-12-310001402479us-gaap:ConstructionInProgressMember2023-06-300001402479us-gaap:ConstructionInProgressMember2022-12-310001402479us-gaap:IntellectualPropertyMember2023-06-300001402479us-gaap:IntellectualPropertyMember2022-12-310001402479us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-06-300001402479us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001402479medavail:WebsiteAndMobileApplicationMember2023-06-300001402479medavail:WebsiteAndMobileApplicationMember2022-12-310001402479us-gaap:OtherIntangibleAssetsMember2023-06-300001402479us-gaap:OtherIntangibleAssetsMember2022-12-310001402479medavail:SVBTermLoanMemberus-gaap:SecuredDebtMember2023-06-300001402479medavail:SVBTermLoanMemberus-gaap:SecuredDebtMember2022-12-310001402479medavail:SVBTermLoanMemberus-gaap:SecuredDebtMemberus-gaap:PrimeRateMember2023-01-012023-06-3000014024792023-02-102023-02-100001402479medavail:SVBWarrantsMember2023-02-100001402479medavail:SiliconValleyBankMember2023-03-290001402479medavail:SiliconValleyBankMember2023-06-300001402479medavail:OtherFinancialInstitutionMember2023-06-300001402479us-gaap:RestrictedStockUnitsRSUMember2023-06-300001402479us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001402479us-gaap:RestrictedStockUnitsRSUMember2022-12-310001402479medavail:A2020PlanMember2023-06-300001402479medavail:A2020PlanMember2022-12-310001402479medavail:A2022InducementPlanMember2023-06-300001402479medavail:A2022InducementPlanMember2022-12-310001402479us-gaap:PrivatePlacementMember2022-03-30medavail:closing0001402479medavail:WarrantsIssuedApril2022Memberus-gaap:PrivatePlacementMember2022-04-042022-04-040001402479medavail:WarrantsIssuedApril2022Memberus-gaap:PrivatePlacementMember2022-04-040001402479us-gaap:PrivatePlacementMembermedavail:WarrantsIssuedJuly2022Member2022-07-012022-07-010001402479us-gaap:PrivatePlacementMembermedavail:WarrantsIssuedJuly2022Member2022-07-010001402479medavail:SVBWarrantsMember2023-06-160001402479medavail:SVBWarrantsMember2023-06-300001402479medavail:SVBWarrantsMember2023-01-012023-06-300001402479medavail:PreFundedWarrantMember2023-03-090001402479medavail:PreFundedWarrantMember2023-03-092023-03-090001402479medavail:SeriesAWarrantMember2023-03-090001402479medavail:PreFundedWarrantMember2023-03-130001402479medavail:SeriesAWarrantMember2023-03-130001402479medavail:PreFundedWarrantMember2023-06-140001402479medavail:SeriesAWarrantMember2023-06-140001402479medavail:PreFundedWarrantMember2023-04-012023-06-300001402479medavail:PreFundedWarrantMember2023-01-012023-06-300001402479medavail:SeriesAWarrantMember2023-01-012023-06-300001402479medavail:SeriesAWarrantMember2023-04-012023-06-300001402479medavail:PreFundedWarrantMember2023-06-300001402479medavail:SeriesAWarrantMember2023-06-300001402479medavail:PharmacyServicesBusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-04-012023-06-300001402479medavail:PharmacyServicesBusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2022-04-012022-06-300001402479medavail:PharmacyServicesBusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-01-012023-06-300001402479medavail:PharmacyServicesBusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2022-01-012022-06-300001402479medavail:PharmacyServicesBusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-06-300001402479medavail:PharmacyServicesBusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2022-12-310001402479us-gaap:SubsequentEventMember2023-07-300001402479us-gaap:SubsequentEventMember2023-07-3100014024792023-06-142023-06-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to_____
Commission File Number 001-36533

MEDAVAIL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware90-0772394
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
4720 East Cotton Gin Loop, Suite 220, Phoenix, Arizona
85040
(Address of principal executive offices)(Zip Code)
(877) 830-0826
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareMDVLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of August 8, 2023, there were 1,613,911 shares of the registrant’s common stock outstanding.





MedAvail Holdings, Inc.
Form 10-Q
For the Three and Six Months Ended June 30, 2023

TABLE OF CONTENTS

Page
PART I
Item 1.Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Stockholders' Equity
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3.Quantitative and Qualitative Disclosures about Market Risk36
Item 4.Controls and Procedures36
PART II
Item 1.Legal Proceedings37
Item 1A.Risk Factors37
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds38
Item 3.Defaults Upon Senior Securities38
Item 4.Mine Safety Disclosures38
Item 5.Other Information38
Item 6.Exhibits39
Signatures40


2

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

•the impact of our decision to exit our pharmacy services business and related asset sales and reductions in force;
•our plans to modify our current products, or develop new products;

•the expected growth of our business and organization;
•our expectations regarding the size of our sales organization and expansion of our sales and marketing efforts;
•our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;
•our ability to obtain and maintain intellectual property protection for our products;
•our ability to expand our business into new geographic markets;
•our compliance with extensive Nasdaq requirements and government laws, rules and regulations both in the United States and internationally;
•our estimates of expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing;
•our ability to identify and develop new and planned products and/or acquire new products;
•existing regulations and regulatory developments in the United States, Canada and other jurisdictions;
•the impact of laws and regulations;
•our financial performance;
•the period over which we estimate our existing cash, cash equivalents and available-for-sale investments will be sufficient to fund our future operating expenses and capital expenditure requirements;
•our anticipated use of our existing resources;
•developments and projections relating to our competitors or our industry; and
•the impact of general market and macroeconomic conditions, the effect of inflationary pressure, including any impact of adverse developments affecting the financial services industry, such as those based on liquidity constraints or concerns and events including the outbreak of war in Ukraine, on our business.

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate. These forward-looking statements are management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K filed
3

with the Securities and Exchange Commission, or SEC. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the SEC as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

4

PART I
Item 1. Financial Statements
MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)


June 30, 2023December 31, 2022
Assets
Current assets:
Cash and cash equivalents$14,359 $11,444 
Restricted cash676 676 
Accounts receivable292 404 
Inventories10,065 8,817 
Prepaid expenses and other current assets711 2,569 
Current assets from discontinued operations946 4,842 
Total current assets27,049 28,752 
Property, plant and equipment, net732 438 
Intangible assets, net657 451 
Right-of-use assets701 624 
Other assets40 30 
Long-term assets from discontinued operations729 2,837 
Total assets$29,908 $33,132 


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Balance Sheets (Continued)
(Unaudited)
(in thousands, except share and per share amounts)

June 30, 2023December 31, 2022
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$796 $818 
Accrued liabilities462 552 
Accrued payroll and benefits832 1,379 
Deferred revenue346 152 
Current portion of lease obligations208 246 
Current liabilities from discontinued operations1,512 2,794 
Total current liabilities4,156 5,941 
Long-term debt, net1,506 4,798 
Long-term portion of lease obligations
550 441 
Long-term liabilities from discontinued operations651 1,128 
Total liabilities6,863 12,308 
Commitments and contingencies (Note 10)
Stockholders' equity:
Common shares ($0.001 par value, 300,000,000 shares authorized, 1,613,870 and 1,603,394 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively) (1)
2 2 
Warrants
35,480 11,148 
Additional paid-in-capital257,318 256,308 
Accumulated other comprehensive loss(6,928)(6,928)
Accumulated deficit(262,827)(239,706)
Total stockholders' equity23,045 20,824 
Total liabilities and stockholders' equity$29,908 $33,132 
(1) Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except share and per share amounts)


Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Revenue:
Hardware and subscription revenue$127 $289 $431 $454 
Service revenue278 254 594 354 
Total revenue405 543 1,025 808 
Cost of products sold and services:
Hardware cost of products sold131 221 376 301 
Service costs96 115 214 166 
Total cost of products sold and services227 336 590 467 
Other operating expenses:
General and administrative4,365 5,053 9,325 10,488 
Selling and marketing122 55 254 155 
Research and development145 219 321 477 
Total operating expense4,632 5,327 9,900 11,120 
Operating loss(4,454)(5,120)(9,465)(10,779)
Loss on issuance of warrants— — (10,424)— 
(Loss) gain from change in fair value of warrant liabilities(896)— 2,149 — 
Interest income— — 1 1 
Interest expense(146)(273)(315)(524)
Loss before income taxes(5,496)(5,393)(18,054)(11,302)
Income tax expense— (24)— (24)
Net loss and comprehensive loss from continued operations(5,496)(5,417)(18,054)(11,326)
Discontinued operations:
Loss from discontinued operations(295)(6,301)(5,067)(13,414)
Net loss$(5,791)$(11,718)$(23,121)$(24,740)
Basic and diluted net loss per share: (1)
Loss from continued operations$(3.06)$(3.91)$(10.61)$(11.05)
Loss from discontinued operations$(0.16)$(4.54)$(2.98)$(13.09)
Weighted average shares outstanding - basic and diluted (1)
1,798,2451,387,1341,702,3601,024,800
(1) Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)
(in thousands, except share amounts)

Common Shares (1)
Warrants
Additional Paid-in-Capital (1)
Accumulated DeficitAccumulated Other Comprehensive LossTotal Stockholders' Equity
SharesAmount
Balance at March 31, 20231,609,613 $2 $11,205 $256,926 $(257,036)$(6,928)$4,169 
Net loss— — — — (5,791)— (5,791)
Issuance of common warrant shares through private placement — — 24,275 — — — 24,275 
Shares issued for vested RSUs3,483 — — — — — — 
Issuance of common shares under employee stock purchase plan774 — — 11 — — 11 
Share-based compensation— — — 381 — — 381 
Balance at June 30, 20231,613,870 $2 $35,480 $257,318 $(262,827)$(6,928)$23,045 
Balance at December 31, 2022
1,603,394 $2 $11,148 $256,308 $(239,706)$(6,928)$20,824 
Net loss— — — — (23,121)— (23,121)
Issuance of common warrant shares through private placement — — 24,332 — — — 24,332 
Shares issued for vested RSUs9,702 — — — — — — 
Issuance of common shares under employee stock purchase plan774 — — 11 — — 11 
Share-based compensation— — — 999 — — 999 
Balance at June 30, 20231,613,870 $2 $35,480 $257,318 $(262,827)$(6,928)$23,045 
Balance at March 31, 2022658,178$— $1,373 $217,282 $(205,112)$(6,928)$6,615 
Net loss—— — — (11,718)— (11,718)
Issuance of common shares 752,9411 — 37,200 — — 37,201 
Issuance of warrants —— 7,503 (7,503)— — — 
Issuance of common shares under employee stock purchase plan1,080— — 77 — — 77 
Share-based compensation— — 612 — — 612 
Balance at June 30, 20221,412,199$1 $8,876 $247,668 $(216,830)$(6,928)$32,787 
Balance at December 31, 2021658,041$— $1,373 $216,718 $(192,090)$(6,928)$19,073 
Net loss—— — — (24,740)— (24,740)
Issuance of common shares752,9411 — 37,200 — — 37,201 
Issuance of warrants—— 7,503 (7,503)— — — 
Issuance of common warrant shares through private placement 137— — — — — — 
Issuance of common shares under employee stock purchase plan1,080— — 77 — — 77 
Share-based compensation—— — 1,176 — — 1,176 
Balance at June 30, 20221,412,199$1 $8,876 $247,668 $(216,830)$(6,928)$32,787 
(1) Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



8

MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Six Months Ended June 30,
20232022
Cash flows from operating activities:
Net loss$(23,121)$(24,740)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment729 573 
Amortization of intangible assets68 295 
Amortization of leased assets518 384 
Loss on disposal of net assets from discontinued operations319 — 
Loss on issuance of warrants10,424 — 
Gain from change in fair value of warrants(2,149)— 
Credit losses on accounts receivable91 59 
Term loan discount amortization and interest accretion on debt146 141 
Share-based compensation expense999 1,176 
Changes in operating assets and liabilities:
Accounts receivable880 (946)
Inventory1,585 (2,380)
Prepaid expenses and other current assets1,952 (1,185)
Accounts payable(868)700 
Accrued liabilities223 166 
Accrued payroll and benefits(1,300)314 
Deferred revenue194 8 
Operating lease liability due to cash payments(279)(279)
Net cash used in operating activities(9,589)(25,714)
Cash flows from investing activities:
Purchase of property, plant and equipment— (634)
Return (payment) of security deposits51 (5)
Purchase of intangible assets and other assets(109)(1,087)
Net cash used in investing activities(58)(1,726)
Cash flows from financing activities:
Proceeds from issuance of warrants in private placement15,999 37,201 
Issuance of common shares upon exercise of employee stock purchase plan11 77 
Payment of debt issuance costs(380)— 
Repayment of debt(3,000)— 
Payments on finance lease obligations
(68)(49)
Net cash provided by financing activities12,562 37,229 
Net increase in cash, cash equivalents and restricted cash2,915 9,789 
Cash, cash equivalents and restricted cash at beginning of period12,120 20,089 
Cash, cash equivalents and restricted cash at end of period$15,035 $29,878 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
9

MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows (Continued)
(Unaudited)
(in thousands)
Six Months Ended June 30,
20232022
Supplemental cash flow information:
Cash paid for interest$242 $376 
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment$— $676 
Purchase of property, plant and equipment in accounts payable$— $62 
Purchases of intangible assets in accounts payable$151 $— 
Fair value of warrant issued upon closing of private placement$— $7,503 
Reclassification of warrants from liability to equity classified$24,332 $— 
Lease liabilities arising from obtaining right of use assets:
Operating leases$— $206 
Finance leases$230 $73 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
10



MEDAVAIL HOLDINGS, INC.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
NOTE 1 - NATURE OF OPERATIONS
MedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter also has the ability to facilitate live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control.
Exit of Pharmacy Services and SpotRx
On January 19, 2023, the Company announced a plan to exit the pharmacy services business to focus on its pharmacy technology business. In connection with its decision to exit the pharmacy services business, the Company initiated a reduction in force, in which employees of the pharmacy services business, representing at that time approximately 75% of the Company’s full-time employees, were terminated, effective January 18, 2023. The Company initiated the reduction in force to preserve capital and use its limited resources to pursue the pharmacy technology business.

On January 20, 2023, the Company entered into an Asset Purchase and Sale Agreement, as amended, with German Dobson CVS, L.L.C., Garfield Beach CVS, L.L.C., Longs Drug Stores California, L.L.C., Woodward Detroit CVS, L.L.C. and Holiday CVS, L.L.C., or CVS, pursuant to which the Company agreed to sell to CVS certain assets, including pharmacy records, and inventory from SpotRx pharmacies located in Tucson and Phoenix, Arizona; Buena Park, Laguna Hills and San Fernando, California; Southfield, Michigan; and in Orlando and Tampa, Florida. The transaction closed on February 9, 2023, for a final purchase price of $2.9 million (subject to $0.1 million in fees and a $0.2 million indemnification holdback). Upon closing, the pharmacy assets purchased by CVS were transferred from the SpotRx pharmacies to nearby CVS pharmacy locations.

Prior to the change in reporting for discontinued operations, the pharmacy services business comprised approximately 97% of the Company’s total revenues for the year ended December 31, 2022, and inventory from SpotRx pharmacies comprised approximately $3.0 million, or 9%, of total consolidated assets as of December 31, 2022. Pharmacy service business assets that were not sold to CVS have been or are expected to be primarily reabsorbed, settled, sold or abandoned. As of March 31, 2023, the Company had substantially completed its exit from the pharmacy services business.

The accounting requirements for reporting the pharmacy services business as a discontinued operation were met during the three months ended March 31, 2023. Accordingly, the condensed consolidated financial statements and notes to the condensed consolidated financial statements reflect the results of the pharmacy service business as a discontinued operation for the periods presented. See Note 13 for additional information.

Reverse Stock Split
On June 14, 2023, the stockholders of the Company approved resolutions to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, par value $0.001 per share, at a specific ratio within a range of 1-for-30 to 1-for-80, with the specific ratio to be determined by the Board of Directors in its sole discretion without further stockholder approval (the “Reverse Stock Split”). On July 14, 2023, the Board of Directors approved a Reverse Stock Split ratio of 1-for-50, such that every 50 shares of the Company’s common stock was combined into one share of common stock, effective at 5:00 p.m. Eastern Time on July 31, 2023. Except as otherwise noted, all references to common stock, preferred stock, restricted stock units, stock options, and warrants and all per share information throughout this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the Reverse Stock Split.

NOTE 2 - LIQUIDITY
The condensed consolidated financial statements for the three and six months ended June 30, 2023 and as of December 31, 2022, were prepared on the basis of a going concern which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business.

On March 9, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors, or the Investors, for the private placement of securities. Upon close of the transaction, the Company received gross proceeds from the offering of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from this offering to fund one-time costs
11


associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. Pursuant to the offering, on March 13, 2023, the Company issued pre-funded warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.001 per share, or Pre-Funded Warrants, and on June 16, 2023, the Company issued Series A warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.38544 per share, or Series A Warrants. See Note 13.

As of June 30, 2023, the Company had $15.0 million in cash and cash equivalents and restricted cash, and an accumulated deficit of $262.8 million. Furthermore, net cash used in operating activities for the six months ended June 30, 2023 and 2022 was $9.6 million and $25.7 million, respectively. Since inception through June 30, 2023, the Company has continually incurred losses from its operations, which have been financed primarily from net cash proceeds from sales of common stock and warrants in private placements, sales of redeemable preferred stock and debt.

Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the Company’s ability to continue as a going concern. If substantial doubt does exist, management should determine if there are plans in place which alleviate that doubt. As of December 31, 2021, and through the nine months ended September 30, 2022, the Company had identified substantial doubt as to the Company’s ability to continue as a going concern. As of December 31, 2022, there was no substantial doubt as to the Company's ability to continue as a going concern. During the first quarter of 2023, the Company raised capital in a private placement and reduced operating costs by exiting its pharmacy services business. As a result, after considering the Company's ongoing cash requirements to fund operations, management determined that the Company has sufficient financial resources to continue operations for one year from the date of issuance of these financial statements, with no substantial doubt as to the Company’s ability to continue as a going concern.

NOTE 3 - BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information, and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements.
The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. The Company's critical accounting policies are those that are both most important to its financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company is not aware of any events or circumstances which would require update to its estimates or judgements as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2022 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or SEC, on April 14, 2023 and retrospectively revised and recast for discontinued operation presentation in the Company's Current Report on Form 8-K filed with the SEC on June 29, 2023.
Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

As noted in Note 1, the Company substantially completed its exit from the pharmacy services business as of March 31, 2023. As a result, the Company has reported the operating results of its pharmacy services business in the loss from discontinued operations line in the condensed consolidated statements of operations for all periods presented. In addition, related assets and liabilities were reported as assets of discontinued operations and liabilities of discontinued operations in the condensed consolidated balance sheets for all periods presented. Unless otherwise noted, the discussion within these notes to the condensed consolidated financial statements relates to continuing operations comprised of the pharmacy technology business. See Note 13 for additional information on discontinued operations.

12


NOTE 4 - RECENT ACCOUNTING PRONOUNCEMENTS
Recently Issued Accounting Standards Not Yet Adopted

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions
In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, or ASU 2022-03. The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements.

There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated financial statements through the reporting date.

Recently Adopted Accounting Standards

Measurement of Credit Losses on Financial Statements
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments”, or ASU 2016-13, supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, or ASU 2018-19. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, and for fiscal years beginning after December 15, 2022 for all other public business entities and private companies, with early adoption permitted. Effective January 1, 2023, the Company adopted ASU No. 2016-13. The impact of adoption of ASU 2016-13 was not material to its consolidated financial statements.

NOTE 5 - LOSS PER SHARE
Basic loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.
The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding. After these warrants are exercised, the related issued and outstanding common shares are included in weighted average shares outstanding:

SharesIssuance DateExercise Date
386November 18, 2020Outstanding
996,264March 9, 2023Outstanding
During the three and six months ended June 30, 2023 and 2022, there was no dilutive effect from stock options, restricted stock units, or other warrants due to the Company’s net loss position. As of June 30, 2023 and 2022, there were 1.6 million and 94 thousand shares of dilutive common stock, respectively, from underlying outstanding options, RSUs and issued warrants that were not included in the diluted shares calculation because their inclusion would have been antidilutive.

NOTE 6 - FAIR VALUE MEASUREMENTS
Fair value measurements are categorized in one of the following three levels based on the lowest level input that is significant to the fair value measurement in its entirety:
Level 1 - Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than quoted prices in active markets for identical assets or liabilities include:
a.quoted prices for similar assets or liabilities in active markets;
b.quoted prices for identical or similar assets or liabilities in inactive markets;
13


c.inputs other than quoted prices that are observable for the asset or liability;
d.inputs that are derived principally from or corroborated by observable market data by correlation or other means.
If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
Level 3- Inputs to the valuation methodology are unobservable (i.e., supported by little or no market activity) and significant to the fair value measure.
As of June 30, 2023 and December 31, 2022, there were no assets and liabilities accounted for at fair value on a reoccurring basis. However,on March 9, 2023, the Company entered into a Securities Purchase Agreement, or 2023 Purchase Agreement, with certain investors. Pursuant to the 2023 Purchase Agreement, the Company agreed to issue Pre-Funded Warrants and Series A Warrants. Consequently, the Company initially identified these warrants as liabilities and measured them at fair value on March 13, 2023, and subsequently remeasured the fair value of these warrant liabilities through June 14, 2023. The Company utilized the Black Scholes valuation methodology to determine the fair value of these warrants. The fair value of these warrants was classified as Level 3 with key Level 3 inputs of exercise price, term, and volatility. Any related loss or gain on the change in fair value of these warrant liabilities was recorded in the "Loss on issuance of warrants" and "(Loss) gain in change in fair value of warrant liabilities" line items within the condensed consolidated statements of operations and comprehensive loss. On June 14, 2023, the Company evaluated these warrant liabilities for equity criteria classification and consequently reclassified these warrant liabilities to equity. See Note 12, for further details regarding the Company's Pre-Funded and Series-A Warrants, the fair value measurement of these Warrants and subsequent equity classification.
The following table presents the changes in the fair value of the Pre-Funded and Series A Warrants during the six months ended June 30, 2023:
(in thousands)Pre-Funded Warrant
Liability		Series-A Warrant
Liability		Loss on Issuance of WarrantsGain from Change in Fair Value of Warrant Liabilities
Measurement at March 13, 2023$15,940 $10,484 $(10,424)$— 
Change in fair value$(996)$(1,153)— 2,149 
Measurement at June 14, 2023$14,944 $9,331 
The Company's carrying amount of cash and cash equivalents and restricted cash approximates fair value.

NOTE 7 - BALANCE SHEET AND OTHER INFORMATION
Restricted Cash
The Company considers cash to be restricted when withdrawal or general use is legally restricted. In 2021 pursuant to a Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.7 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in cash and cash equivalents presented in the condensed consolidated statements of cash flows.
Accounts Receivable
Accounts receivable are primarily comprised of trade receivables presented net of allowance for doubtful accounts when estimable and present. The Company maintains an allowance for doubtful accounts based on its assessment of the collectability of amounts owed by customers. The allowance consists of known specific troubled accounts as well as an amount based on overall estimated potential uncollectible accounts receivable based on historical experience. As of June 30, 2023 and December 31, 2022, based upon its historical collections experience, the Company had no credit risk balances that required the Company to reserve an allowance for doubtful accounts.

Inventories

The following table presents detail of inventory balances:
14


June 30,December 31,
(in thousands)20232022
Inventory:
MedCenter hardware$7,924 $8,154 
Spare parts2,141 663 
Total inventory$10,065 $8,817 
MedCenter hardware recognized in hardware cost of products sold was $103 thousand and $176 thousand during the three months ended June 30, 2023 and 2022, respectively, and $314 thousand and $232 thousand during the six months ended June 30, 2023 and 2022, respectively.

Prepaid Expenses and Other Current Assets

The following table presents prepaid expenses and other current assets balances:
June 30,December 31,
(in thousands)20232022
Prepaid expenses and other current assets:
Prepaid MedCenter inventory$— $1,359 
Prepaid insurance467 921 
Other244 289 
Total prepaid expenses and other current assets$711 $2,569 
Property, Plant and Equipment
The following tables present property, plant and equipment balances:
Estimated useful livesJune 30,December 31,
(in thousands)20232022
Property, plant and equipment:
MedCenter equipment
8 years
$1,530 $1,357 
IT equipment
1 - 3 years
2,002 1,908 
Leasehold improvementslesser of useful life or term of lease316 316 
General plant and equipment
5 - 8 years
376 373 
Office furniture and equipment
5 - 8 years
332 217 
Vehicles
5 years
36 36 
Construction-in-process5 5 
Total historical cost4,597 4,212 
Accumulated depreciation(3,865)(3,774)
Total property, plant and equipment, net$732 $438 
Depreciation expense of property and equipment was $57 thousand and $57 thousand for the three months ended June 30, 2023 and 2022, respectively, and $90 thousand and $117 thousand for the six months ended June 30, 2023 and 2022, respectively. Depreciation expense included in hardware cost of products sold was $2 thousand and $26 thousand for the three months ended June 30, 2023 and 2022, respectively, and $11 thousand and $52 thousand for the six months ended June 30, 2023 and 2022, respectively.

15


Intangible Assets

The following table presents intangible asset balances:
June 30,December 31,
(in thousands)20232022
Gross intangible assets:
Intellectual property$3,857 $3,857 
Software2,337 2,200 
Website and mobile application534 534 
Other123 — 
Total intangible assets6,851 6,591 
Accumulated amortization:
Intellectual property(3,857)(3,857)
Software(1,801)(1,749)
Website and mobile application(534)(534)
Other(2)— 
Total accumulated amortization(6,194)(6,140)
Total intangible assets, net$657 $451 

Amortization expense of intangible assets was $28 thousand and $20 thousand for the three months ended June 30, 2023 and 2022, respectively, and $54 thousand and $22 thousand for the six months ended June 30, 2023 and 2022, respectively, and are included in hardware cost of products sold and general and administrative operating expenses.

Lessee Leases

Balance sheet amounts for lease assets and leases liabilities are as follows:
June 30,December 31,
(in thousands)20232022
Lease Assets:
Operating$499$620
Finance2024
Total lease assets$701$624
Lease liabilities:
Operating:
Current$173 $241 
Long-term382 441 
Finance:
Current35 5 
Long-term168 — 
Total lease liabilities$758 $687 
16


The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows:
June 30,December 31,
20232022
Finance leases:
Weighted-average remaining lease term (years)4.50.5
Weighted-average discount rate11.5 %6.0 %
Operating leases:
Weighted-average remaining lease term (years)3.43.6
Weighted-average discount rate6.1 %7.3 %
Maturities of operating leases liabilities are as follows:
(in thousands)
Remaining period in 2023$135 
2024148 
2025152 
2026157 
202737 
Total operating lease payments629 
Less: present value discount(74)
Total operating leases$555 

Maturities of finance lease liabilities are as follows:
(in thousands)
Remaining period in 2023$29 
202458 
202558 
202658 
202758 
Total finance lease payments261 
Less: imputed interest(58)
Total finance leases$203 

Operating lease expense was $25 thousand and $126 thousand for the three months ended June 30, 2023 and 2022, respectively, and $154 thousand and $256 thousand for the six months ended June 30, 2023 and 2022, respectively.

NOTE 8 - DEBT
The following table presents debt balances:
June 30,December 31,
(in thousands)20232022
Term loan$2,002 $5,182 
Term loan issuance costs, net(496)(384)
Long-term debt, net$1,506 $4,798 
17


Maturities of debt liabilities are as follows:
(in thousands)
Remaining period in 2023$— 
2024668 
20251,000 
2026334 
Total debt$2,002 

Term Loan
The Term loan bears interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (12.25% at June 30, 2023). The term loan matures on April 1, 2026. The remaining principal repayment will commence on May 1, 2024 in equal monthly installments of the outstanding Loan balance through the maturity date.

First Amendment, Consent and Default Waiver to Loan and Security Agreement
On February 10, 2023, the Company entered into the First Amendment, Consent and Default Waiver to Loan and Security Agreement or the Loan Amendment and Consent, with each of Silicon Valley Bank, a California corporation, and an authorized foreign bank under the Bank Act (Canada), and SVB Innovation Credit Fund VIII, L.P., a Delaware limited partnership, or together SVB. Among other matters, the Loan Amendment and Consent provides SVB’s consent to the sale of certain assets related to the Company’s pharmacy services business pursuant to the previously announced Asset Purchase Agreement. The Loan Amendment and Consent also provides that upon the closing of the asset sale, the Company would pay SVB $3.4 million, which includes $0.4 million of the Final Payment (as defined in the Loan Amendment and Consent) and prepayment of $3.0 million of Term Loan Advances (as defined in the Loan Amendment and Consent), with SVB waiving the prepayment premium due on all Term Loan Advances prepaid by the Company prior to February 10, 2023. The Loan Amendment and Consent also includes SVB's waiver of any legal action or enforcement of rights and remedies with respect to certain specified defaults arising prior to February 10, 2023.

On February 10, 2023, in connection with the Loan Amendment and Consent, the Company issued warrants, or the SVB Warrants, to SVB for the purchase of up to an aggregate of 4 thousand shares of common stock at a per share exercise price of $16.37, with an expiration date of February 10, 2035. Pursuant to the terms of the SVB Warrants, the number of shares and the exercise price were adjusted as of June 16, 2023. See Note 12.

SVB Letter Agreement

On March 10, 2023, SVB, based in Santa Clara, California, was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. On March 10, 2023, the Federal Deposit Insurance Corporation (the “FDIC”) took control of SVB and created the National Bank of Santa Clara to hold the deposits of SVB after SVB was unable to continue their operations.

On March 13, 2023, the Company was informed by SVB that the Company was still bound by the terms, conditions, and covenants of the Company’s Loan and Security Agreement with SVB, or the Loan Agreement, and the Loan Amendment and Consent. On March 29, 2023, the Company entered into a Letter Agreement, or Letter Agreement, with each of (a) Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB Successor, in its capacity as administrative agent and collateral agent, (b) SVB Successor, as a lender, and (c) SVB Innovation Credit Fund VIII, L.P., or SVB Capital, as a lender, and obtained a waiver for any event of default occurring prior to March 29, 2023, to include the year ended December 31, 2022. The Letter Agreement also amends the Loan Agreement to provide that the Company is only required to maintain on deposit at SVB Successor or its affiliates, at least 50% of the aggregate dollar value of all of the Company accounts at all financial institutions.

As of June 30, 2023, the Company had approximately $9.7 million on deposit with SVB Successor and $5.3 million on deposit with another financial institution and was in compliance with all required covenants of the Loan Agreement. The Company continues to monitor the circumstances surrounding SVB and does not anticipate such circumstances will have a material impact on the Company's financial condition, operations, or on the Loan Agreement with SVB Successor. As of the date of filing this Quarterly Report on Form 10-Q, the Company has full access to and control over all of its cash and cash equivalents across all financial institutions.

18


NOTE 9 - INCOME TAXES
The Company incurred minimal income tax expense for the three months ended June 30, 2023 and 2022, due to ongoing losses and minimum state income tax obligations. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses.
As of June 30, 2023 and December 31, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.

NOTE 10 - COMMITMENTS AND CONTINGENCIES
Litigation
The Company is and, from time to time may in the future become, involved in legal proceedings, claims and litigation in the ordinary course of business. The Company has become subject to certain demands, and claims from former employees relating to the reduction in force the Company implemented in connection with the restructuring of the company and the disposition of its pharmacy services business. The Company intends to vigorously defend itself against such pending and threatened actions. The Company cannot determine a reasonable estimate of the maximum possible loss or range of loss for pending or threatened matters given that they are at various stages of the litigation process and each case is subject to the inherent uncertainties of litigation. In management’s opinion, based on currently available information, any potential loss resulting from the resolution of these matters is not expected to have a material adverse effect on the Company’s results of operations, financial position, or cash flows.

NOTE 11 - SHARE-BASED COMPENSATION
Share-based Compensation
The following table presents the Company's expense related to share-based compensation, in thousands:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Share-based compensation $381 $612 $999 $1,176 
Expense remaining to be recognized for unvested option awards from the 2012, 2018, 2020 and 2022 plans as of June 30, 2023, was $1.5 million, which will be recognized on a weighted average basis over the next 2.0 years. Expense remaining to be recognized for unvested RSU awards as of June 30, 2023, was $0.9 million, which will be recognized on a weighted average basis over the next 1.5 years.

The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2023:
(in thousands, except for share and per share amounts)Number of AwardsWeighted Average Exercise PriceWeighted Average Fair ValueWeighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value
Outstanding, at December 31, 202287,995 $94.64 $57.26 $— 
Granted43,637 15.25 11.66 1 
Exercised/Released— — — — 
Expired(62)622.69 372.66 — 
Forfeited(28,362)95.49 53.27 — 
Outstanding, end of period, at June 30, 2023103,208 $60.66 $39.03 9.11$— 
Vested and exercisable, at June 30, 2023 37,186 107.53 66.14 8.18— 
Vested and unvested exercisable, at June 30, 202337,186 107.53 66.14 8.18— 
Vested and expected to vest, at June 30, 2023100,542 61.91 39.79 9.09— 
The following table present outstanding RSU awards activity during the six months ended June 30, 2023:

19


Number of AwardsWeighted Average Exercise PriceWeighted Average Grant Date Fair ValueWeighted Average Remaining Contractual Life (Years)
Unvested outstanding, at December 31, 202247,531 $— $65.30 — 
Granted— $— $— — 
Exercised/Released(9,702)$15.84 $77.02 — 
Cancelled/Forfeited(18,983)$— $62.67 — 
Expired— $— $— — 
Unvested outstanding, at June 30, 202318,846 $— $61.99 14.29
Vested outstanding shares at June 30, 2023— $— $— — 

As of June 30, 2023 and December 31, 2022, there was an aggregate of 93 thousand and 46 thousand shares of common stock, respectively, available for grant under the 2020 Plan. As of June 30, 2023 and December 31, 2022, there was an aggregate of 22 thousand and 4 thousand shares of common stock, respectively, available for grant under the 2022 Inducement plan.

NOTE 12 - WARRANTS
The Company effected the Reverse Stock Split on July 31, 2023, pursuant to which every 50 shares of the Company’s common stock was combined into one share. The number of underlying shares and the exercise price of each of the Company’s warrants were proportionately adjusted to give effect to the Reverse Stock Split. The Reverse Stock Split had no effect on the accounting for the Company’s warrants.

2022 Warrants
On March 30, 2022, the Company entered into a Securities Purchase Agreement with certain investors. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell in a private placement, or the 2022 Private Placement, up to 942 thousand shares of the Company’s common stock and warrants, or the 2022 Warrants, to purchase up to 470 thousand shares of common stock. The securities were sold at two closings at a price per share of $50.13.

At the first closing on April 4, 2022, the Company sold 75.2 thousand shares of common stock and 2022 Warrants to purchase up to 376 thousand shares of common stock, for gross proceeds of $40.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on April 4, 2022 had a fair value of $9.2 million, a 5 year term and a per share exercise price of $62.50. A second and final closing occurred on July 1, 2022, at which the Company sold an additional 188 thousand shares of common stock and 2022 Warrants to purchase up to 94.0 thousand shares of common stock, for gross proceeds of $10.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on July 1, 2022 had a fair value of $4.5 million, a 5 year term and a per share exercise price of $62.50.

None of the 2022 Warrants have been exercised or expired as of June 30, 2023 and December 31, 2022. The 2022 Warrants meet equity classification requirements and therefore are classified in our stockholders’ equity.

2023 SVB Warrants
On February 10, 2023, as part of the First Amendment to the Loan and Security Agreement with Silicon Valley Bank ("SVB") (see Note 8), the Company issued warrants, or SVB Warrants, to purchase up to an aggregate of 4 thousand shares of common stock at a per share exercise price of $16.37, with an expiration date of February 10, 2035. The number of shares and the exercise price were subject to adjustment, or the Special Adjustment for Warrant Shares, upon the occurrence of the last closing of the Company’s next equity financing, as set forth in the SVB Warrants.

On March 9, 2023, the Company entered into the 2023 Purchase Agreement, with certain institutional investors, pursuant to which the Company sold securities in a private placement at two closings that constituted the Company’s next equity financing within the meaning of the SVB Warrants. The first closing occurred on March 13, 2023 and the second closing occurred on June 16, 2023. On June 16, 2023, pursuant the Special Adjustment for Warrant Shares, the number of shares of common stock underlying the SVB Warrants increased to 5.4 thousand and the per share exercise price decreased to $10.25.

Upon the grant date, February 10, 2023, the fair value of the SVB Warrants was approximately $57 thousand measured using the Black-Scholes option pricing model. The SVB Warrants met equity classification requirement under ASC 815 - Derivative and Hedging, specifically
20


due to the warrants having a limit on the number of shares the Company is required to deliver upon exercise and the warrant not including cash-settled top-off or make-whole provisions, as well as, other conditions. As such, the SVB Warrants met the equity classification requirements and are classified in the Company's stockholders' equity. None of the SVB Warrants have been exercised or expired as of June 30, 2023.

The key input assumptions utilized in the valuation of the SVB Warrants were as follows:
Grant date
Market price$16.00
Exercise price$16.37
Term (Years)12
Volatility85%
Risk Free Rate3.68%

2023 Pre-Funded and Series A Warrants
As noted above, on March 9, 2023, the Company entered into the 2023 Purchase Agreement with certain investors. Pursuant to the 2023 Purchase Agreement, the Company agreed to issue Pre-Funded Warrants and Series A Warrants. On March 13, 2023, at the first closing of the offering, the Company sold at a price of $16.06 per underlying share, Pre-Funded Warrants to purchase up to 996.3 thousand shares of common stock at an exercise price of $0.05 per share for total gross proceeds of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from the offering to fund costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. The number of Pre-Funded Warrants exercisable by investors was limited to 19.99% of the Company’s common stock outstanding immediately prior to the offering pursuant to a listing rule of The Nasdaq Stock Market, which required that the Company obtain stockholder approval of the issuance of shares above this 19.99% cap. The Pre-Funded Warrants were classified as a liability at issuance due to the need for the Company to obtain stockholder approval to settle the instruments in shares.

On March 9, 2023, the Company also agreed to issue Series A Warrants to purchase up to 996.3 thousand shares of common stock with an exercise price of $19.27 per share, which was conditional upon the Company obtaining stockholder approval of the issuance. The Series A Warrants were also classified as a liability as the Company had an irrevocable obligation to obtain stockholder approval of the issuance of the Series A Warrant, and as such did not have sufficient shares to settle the obligation and consequently failed the equity classification requirements pending shareholder approval.

On June 14, 2023, at its annual stockholders’ meeting, the Company obtained the requisite stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company issued the Series A Warrants on June 16, 2023.

Upon grant, March 13, 2023, the fair value of the Pre-Funded Warrants and Series A Warrants was $15.9 million and $10.5 million, respectively. The Company recorded the $10.4 million difference between the offering proceeds and grant date fair value as a loss on issuance of warrants in the statement of operations and comprehensive loss. Subsequent to its grant date fair value measurement, and through June 14, 2023, the Company remeasured the warrants at fair value and recognized a gain from change in fair value of warrants on the statement of operations and comprehensive loss. As of June 14, 2023, the fair value of Pre-Funded Warrants and Series A Warrants was $14.9 million and $9.3 million, respectively. For the three and six months ended June 30, 2023, the Company recognized a loss of $0.9 million and gain of $2.1 million in fair value remeasurement of the Pre-Funded Warrants and Series A Warrants, respectively.

Subsequent to the remeasurement of the Pre-Funded Warrants and Series A Warrants, the Company reassessed the liability classification of these warrants due to the Company obtaining on June 14, 2023, stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company determined that the Pre-Funded Warrants and Series A Warrants met the equity classification requirements, and the warrants were re-classified from liability to equity as of June 14, 2023.

The fair values of the Pre-Funded Warrants and Series A Warrants were measured using the Black-Scholes option pricing model. As of the grant date and June 14, 2023, the key input assumptions utilized in the valuation of the Pre-funded Warrants were as follows:
Grant dateJune 14, 2023
Market price$16.00$15.00
Exercise price$0.05$0.05
Term (Years)*IDFIDF
Volatility85%82%
Risk Free Rate3.70%3.90%
*Warrant is outstanding until fully exercised; as such, the term was measured as indefinite.

The key input assumptions utilized in the valuation of the Series A Warrants were as follows:
21


Grant dateJune 14, 2023
Market price$16.00$15.00
Exercise price$19.27$19.27
Term (Years)54.7
Volatility85%82%
Risk Free Rate3.68%4.10%


NOTE 13 - DISCONTINUED OPERATIONS
As discussed in Note 1 – Nature of Operations – the exit from our pharmacy services business was substantially completed as of March 31, 2023. The pharmacy services business previously was a reportable segment and the exit represents a strategic shift in the Company going forward. Accordingly, with the sale or disposition of its retail pharmacy assets and exit from the pharmacy services business, this transaction meets the accounting requirements for reporting as discontinued operations under ASC 205-20-50 for all periods presented.

The following table summarizes the major income and expense line items from discontinued operations as reported in the condensed consolidated statements of operations and comprehensive loss:

Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2023202220232022
Revenue:
Pharmacy revenue$— $10,641 $3,834 $19,490 
Total revenue— 10,641 3,834 19,490 
Cost of products sold and services:
Pharmacy cost of products sold— 9,931 3,581 18,412 
Total cost of products sold and services— 9,931 3,581 18,412 
Operating expense:
Pharmacy operations157 3,450 1,883 7,170 
General and administrative141 1,242 711 2,560 
Selling and marketing— 2,253 845 4,457 
Research and development— 63 — 299 
Total operating expense298 7,008 3,439 14,486 
Operating loss(298)(6,298)(3,186)(13,408)
Loss from sale and disposition of net assets, and reorganization expenses, net— — (1,885)— 
Interest expense3 (3)4 (6)
Loss from discontinued operations$(295)$(6,301)$(5,067)$(13,414)

Cash used by operating activities by the pharmacy services business totaled $987 thousand and $14.4 million for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash provided by (used in) investing activities from the pharmacy services business totaled $212 thousand and $(428) thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash used in financing activities from the pharmacy services business totaled $47 thousand and $41 thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. Depreciation and amortization expense of the pharmacy services business totaled $895 thousand and $673 thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. The condensed consolidated statements of cash flows included $319 thousand loss on disposal of net assets from discontinued operations, which comprised of losses related to net realizable value adjustments to right of use assets related to leases and prepaid assets, and abandonment of certain property, plant, and equipment related to our discontinued operations.
22



The following table summarizes the major classes of assets and liabilities of the retail pharmacy business as reported on the condensed consolidated balance sheets:
(in thousands)June 30, 2023December 31, 2022
Carrying amounts of major classed of assets included as part of discontinued operations:
Accounts receivable, net$946 $1,805 
Prepaid expenses and other current assets— 94 
Inventories— 2,943 
Total current assets from discontinued operations$946 $4,842 
Intangible assets, net$— $14 
Property plant and equipment, net— 1,194 
Right-of-use assets622 1,461 
Other assets107 168 
Total long-term assets from discontinued operations$729 $2,837 
Total long-term assets from discontinued operations
Accounts payable$162 $857 
Accrued liabilities954 641 
Accrued payroll and benefits81 834 
Current portion of lease obligations315 462 
Total current liabilities from discontinued operations$1,512 $2,794 
Long-term portion of lease obligations$651 $1,128 
Total long-term liabilities from discontinued operations$651 $1,128 


NOTE 14 - STOCKHOLDERS' EQUITY
Reverse Stock Split
On June 14, 2023, the stockholders of the Company approved a one-for-fifty reverse stock split of its outstanding shares of common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on July 31, 2023 (the “Effective Time”). At the Effective Time, every fifty issued and outstanding shares of the Company’s common stock were converted into one share of the Company’s common stock.

The reverse split affected all the stockholders uniformly and did not affect any stockholder’s percentage ownership interests in the Company or proportionate voting power. Each common stockholder held the same percentage of the outstanding common stock immediately following the reverse split as that stockholder did immediately before the reverse split, except for minor adjustments as a result of the treatment of fractional shares.

No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). As a result, the number of common shares outstanding was reduced from 80,693,517 immediately before the Effective Time to 1,613,870.

There was no change in the number of authorized shares of the Company's common stock or preferred stock, or to the par value per share of common stock due to the reverse stock split. All per share amounts and common shares outstanding for all periods presented in the unaudited consolidated financial statements have been adjusted retroactively to reflect the Company's one-for-fifty reverse stock split.

After giving effect to the reverse stock split, the total number of shares of all classes of capital stock that the Company was authorized to issue was 310,000,000 shares, 300,000,000 shares of Common Stock, having a par value of $0.001, and 10,000,000 shares of Preferred Stock, having a par value of $0.001.

23


NOTE 15 - SUBSEQUENT EVENTS
Reverse Stock Split
On June 14, 2023, the stockholders of the Company approved resolutions to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, par value of $0.001 per share, at a specific ratio within a range of 1-for-30 to 1-for-80, with the specific ratio to be fixed within this range to be determined by the Board of Directors in its sole discretion without further loss per share approval. On July 14, 2023, the Board of Directors approved a ratio of 1-for-50, such that every 50 shares of the Company’s common stock were combined into one share of its common stock at 5:00 p.m. Eastern Time on July 31, 2023.
24

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our audited historical condensed consolidated financial statements for the year ended December 31, 2022, which are included in the Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 14, 2023 and retrospectively revised and recast for discontinued operations presentation in the Company's Current Report on Form 8-K filed with the SEC on June 29, 2023, and our unaudited condensed consolidated financial statements and accompanying footnotes for the three months and six months ended June 30, 2023, included in Part I, Item 1., of this Quarterly Report on Form 10-Q.

This quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains statements that are forward-looking regarding future events and our future results subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements.

All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expect. These statements are based on current expectations and assumptions that are subject to risks, uncertainties and other factors. Actual results could differ materially because of the factors discussed above and elsewhere in this Quarterly Report on Form 10-Q. See Part II, Item 1A. "Risk Factors" of this Quarterly Report on Form 10-Q, and Part I, Item 1A. "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2022, as noted above. Unless otherwise indicated or the context otherwise requires, references herein to “MedAvail,” “MedAvail Holdings,” “we,” “us,” “our,” and the “Company” refers to MedAvail Holdings, Inc. and its subsidiaries.
Overview
We are a technology-enabled pharmacy technology services company, and have developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. Through our full-stack pharmacy technology platform, and personal one-on-one service, we bring pharmacy-dispensing capability to the point of care, resulting in lower costs, higher patient satisfaction, improved medication adherence, and better health outcomes.
We offer a unique, pharmacy technology solution which is anchored around our core technology called the MedAvail MedCenter™, or the MedCenter. The MedCenter enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and any other location where onsite prescription dispensing is desired. The MedCenter establishes an audio-visual connection to a live pharmacist enabling remote prescription drug dispensing to occur directly to a patient while still providing real-time supervision by a pharmacist.
Currently, our primary and only commercialization channel is the direct ‘sell-to’ model, whereby we sell or lease the MedCenter hardware technology and provide recurring, one-time, or on demand services related to the MedCenter directly to large healthcare providers and retailers for use within their own pharmacy operations. We deploy the MedCenter solution currently to locations to include, but not limited to, urgent care and emergency medical facility locations, in clinic locations of large healthcare providers, and University campuses.

The MedCenter kiosk works in tandem with our Remote Dispensing System®, or the Remote Dispensing System, which consists of customer-facing software for remote ordering of medications for pick-up at a MedCenter. Supporting our MedCenter kiosks and Remote Dispensing System is our back-end MedPlatform® Enterprise Software, or the MedPlatform Enterprise Software, which controls dispensing and MedCenter monitoring, and supporting Pharmacy Management System software.
Our kiosks come in one model: the M4 MedCenter. The M4 MedCenter is designed to fit in waiting rooms, hallways, and lobbies.
Discontinued Operations
On January 19, 2023, we announced our plan to exit the retail pharmacy services business, or the “Pharmacy Services Business”, to focus on our Pharmacy Technology services. In connection with our exit from the Pharmacy Services Business, we hired a broker and negotiated the sale of certain related pharmacy assets. Our operations following the exit from the Pharmacy Services Business consist solely of our Pharmacy Technology services. On April 6, 2023, we announced that we had completed the transactions contemplated by the Asset Purchase Agreement, including the disposition of the specific assets therein, on February 10, 2023. As of March 31, 2023, we had substantially completed our exit from the Pharmacy Services Business.
Prior to Discontinued Operations, we had two reportable segments: retail pharmacy services and pharmacy technology services. As a result of the retail pharmacy services business exit, the Company met the requirements of ASC 205-20, to report the results of the retail pharmacy services business as a discontinued operation. Accordingly, the operating results for the retail pharmacy services business have therefore been reclassified as a discontinued operation within these condensed consolidated financial statements. As such, unless otherwise noted, the discussion of our operating results, Results of Operations, and Liquidity relate to continuing operations comprised of only our pharmacy technology business for all periods presented.
25


Components of Operating Results for the Six Months Ended June 30, 2023

We have never been profitable and have incurred operating losses each year since inception. Our net losses and comprehensive losses from continued operations were $18.1 million and $11.3 million for the six months ended June 30, 2023 and 2022, respectively. Our net losses, inclusive of discontinued operations, totaled $23.1 million and $24.7 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, we had an accumulated deficit of $262.8 million. Substantially all of our operating losses resulted from expenses incurred in connection general and administrative costs associated with our operations

We expect to incur additional expenses and operating losses as we continue our technology development, redeployment of our MedCenters and right size expenses necessary to operate as a public company. We expect that our operating losses will decrease and turn positive as we execute our growth strategies and focus on our Med Center technologies. If our management accelerates deployment into new states, operating losses could increase in the near-term, as we grow and scale our operations.

As of June 30, 2023, we had cash and cash equivalents of $14.4 million. We will continue to require additional capital to continue our pharmacy technology development and commercialization activities to serve our growing customer base. In April and July 2022, and March 2023, we completed the sale of additional equity through private placement financings, where we raised $40.0 million and $16.0 million in gross proceeds, respectively. Additionally, in June 2021 we added to our liquidity resources through a senior secured term loan with Silicon Valley Bank, or SBV, of $10.0 million, of which we have repaid $8.0 million. As of June 30, 2023, we have an outstanding principal balance of $2.0 million under the term loan. The amount and timing of future funding requirements will depend on many factors, including the pace and results of our growth strategy and capital market conditions. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop product candidates.

Results of Operations for the Three Months Ended June 30, 2023
Revenue
Hardware and Subscription Revenue
We develop and commercialize the MedCenter for direct sale or subscription lease to third-party customers, including some of the world’s largest healthcare providers and systems, as well as large retail chains that provide full retail-pharmacy services using our technology. Hardware and subscription revenue is derived from either sales or subscription leases of the MedCenter to customers.

Service Revenue

Service revenue is derived from recurring subscription revenue from software licensing, platform and software hosting, and software and hardware maintenance; one"-time or on demand service revenue from initial installations, and professional services such as training, pharmacy set-up, and consulting services.

Three Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
(in thousands)
Hardware and subscription revenue:
Hardware revenue$116 $180 $(64)(36)%
Subscription revenue11 109 (98)(90)%
Total hardware and subscription revenue127 289 (162)(56)%
Service revenue:
Software141 141 86 55 64 %
Maintenance and support69 47 22 47 %
Installation85 71 14 20 %
Professional services and other(17)50 (67)(134)%
Total service revenue278 254 24 9 %
Total revenue$405 $543 $(138)(25)%
During the three months ended June 30, 2023, hardware and subscription revenue decreased $162 thousand to $127 thousand compared to the same period in 2022. The $162 thousand decrease was comprised of a $64 thousand decrease primarily due to a decrease in MedCenter sales
26

whereby one less MedCenter was sold over the same prior year period, and a $98 thousand decrease in subscription lease revenue primarily resulting from a decrease in revenue contracts.
During the three months ended June 30, 2023, service revenue remained flat compared to the same period in 2022.

Pharmacy Technology Cost of Products Sold and Services

Hardware Costs of Products
Hardware cost of products sold consists primarily of costs associated with building and customization of MedCenters sold to third-party customers.

Service Costs

Service costs consists primarily of installation, integration, relocation, consumable, and maintenance cost of MedCenters at third-party customer locations, as well as related hosting and software costs.

Three Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
(in thousands)
Hardware cost of products sold:
Hardware$103 $176 $(73)(41)%
Depreciation28 45 (17)(38)%
Total Hardware cost of products sold131 221 (90)(41)%
Service costs:
Professional services7 22 (15)(68)%
Maintenance and support services39 48 (9)(19)%
Installation services50 45 5 11 %
Total service costs96 115 (19)(17)%
Total cost of products sold and services$227 $336 $(109)(32)%
During the three months ended June 30, 2023, hardware cost of products sold decreased $90 thousand to $131 thousand compared to the same period in 2022. The decrease was primarily due to a $73 thousand decrease in hardware costs associated with the decreased number of units sold during the three months ended June 30, 2023 as compared to the same prior year period.
During the three months ended June 30, 2023, service costs were relatively flat as compared to the same prior year period.
General and Administrative
General and administrative expenses consist of personnel costs, facility expenses and expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and share-based compensation. Facility expenses consist of rent and other related costs specific to our corporate and technology activities. Corporate insurance, office supplies and technology expenses are also captured within general and administrative expenses. We incurred and expect to incur expenses as a result of being a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.
We have a stock option plan whereby awards are granted to certain of our employees. The fair value of the stock options and restricted stock units granted by us to our employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. We measure the fair value of the stock options using the Black-Scholes option pricing model as of the grant date. Shares issued upon the exercise of stock options and vesting of restricted stock units are new shares. We estimate forfeitures based on historical experience and expense related to awards is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are expensed.
27

Three Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
General and administrative expenses:(in thousands)
Wages and salaries$1,994 $2,539 $(545)(21)%
Professional services675 598 77 13 %
Share-based compensation381 612 (231)(38)%
Insurance291 433 (142)(33)%
Software licenses and support201 252 (51)(20)%
Rent, utilities, and other699 494 205 41 %
Office and IT supplies59 43 16 37 %
Travel and other employee expenses10 50 (40)(80)%
Depreciation of property, plant and equipment55 32 23 72 %
Total general and administrative expenses$4,365 $5,053 $(688)(14)%
During the three months ended June 30, 2023, general and administrative expenses decreased approximately $688 thousand to $4.4 million compared to the same period in 2022. This decrease was primarily due to reduction in wages and salaries of $545 thousand and share-based compensation of $231 thousand resulting from a reduced headcount due to a reduction in force and lower insurance costs of $142 thousand due to a decrease in director and officer insurance premiums, partially offset by a $205 thousand increase in rent, utilities and other primarily due to increased transportation costs related to MedCenter returns.
Selling and Marketing
Selling and marketing expenses consist of personnel costs, marketing and advertising costs, and marketing related expenses for outside professional services. Wages and salaries consist of compensation costs incurred for all selling and marketing employees including our in clinic customer account managers, and contractors including bonuses, health plans, and severance.
Three Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
Selling and marketing expenses:(in thousands)
Wages and salaries$112 $26 $86 331 %
Travel and other employee expenses— 17 (17)(100)%
Marketing10 12 (2)(17)%
Total selling and marketing expenses$122 $55 $67 122 %
During the three months ended June 30, 2023, selling and marketing expenses increased approximately $67 thousand to $122 thousand compared to the same period in 2022. This increase was primarily due to a $86 thousand increase in salaries and wages resulting from additional increase in headcount related to the sales team, in addition to, one time severance expense paid during the quarter related to the a reduction in force, partially offset by a $17 thousand decrease in travel and other employee expenses.
Research and Development
Research and development expenses represent costs incurred to develop and innovate our MedCenter platform technology, including development work on hardware, software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs.
Three Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
Research and development expenses:(in thousands)
Wages and salaries$143 $178 $(35)(20)%
Other expenses2 41 (39)(95)%
Total research and development expenses$145 $219 $(74)(34)%
During the three months ended June 30, 2023, research and development expenses decreased approximately $74 thousand. This decrease was primarily due to a decrease in headcount as a result of outsourcing research and development costs in order to reduce expenses.
28

Interest Expense
Interest expense consists of accrued interest on outstanding debt and is payable monthly.
Three Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
(in thousands)
Interest expense:
Interest expense$146 $273 $(127)(47)%
Total interest expense$146 $273 $(127)(47)%
During the three months ended June 30, 2023, interest expense decreased $127 thousand compared to the same period in 2022, due to a decrease in outstanding debt during the three months ended June 30, 2023, as compared to the same period in the prior year. Total outstanding debt principal was $2.0 million as of June 30, 2023, as compared to $10.1 million as of June 30, 2022.
Results of Operations for the Six Months Ended June 30, 2023
Revenue
Hardware and Subscription Revenue
We develop and commercialize the MedCenter for direct sale or subscription lease to third-party customers, including some of the world’s largest healthcare providers and systems, as well as large retail chains that provide full retail-pharmacy services using our technology. Hardware revenue is derived from either sales or subscription leases of the MedCenter to customers.

Service Revenue

Service revenue is derived from recurring subscription revenue from software licensing, platform and software hosting, and software and hardware maintenance; and one-time or on demand service revenue from initial installations, and professional services such as training, pharmacy set-up, and consulting services.

Six Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
(in thousands)
Hardware and subscription revenue:
Hardware revenue$372 $236 $136 58 %
Subscription revenue59 218 (159)(73)%
Total hardware and subscription revenue431 454 (23)(5)%
Service revenue:
Software235 133 102 77 %
Maintenance and support125 79 46 58 %
Installation152 77 75 97 %
Professional services and other82 65 17 26 %
Total service revenue594 354 240 68 %
Total revenue$1,025 $808 $217 27 %
During the six months ended June 30, 2023, hardware and subscription revenue decreased $23 thousand to $431 thousand compared to the same period in 2022. The $23 thousand decrease was comprised of a $159 thousand decrease in subscription lease revenue primarily resulting from certain customers shifting their dispensing needs away from our MedCenter platform, partially offset by $136 thousand increase in MedCenter sales whereby two more MedCenters were sold over the same prior year period.
During the six months ended June 30, 2023, service revenue increased $240 thousand to $594 thousand compared to the same period in 2022, primarily due to increased services provided as a result of increased MedCenter sales during the six months ended June 30, 2023, as well as increased software sales from the second half of the prior year period, as compared to the six months ended June 30, 2022.
29


Cost of Products Sold and Services

Hardware Costs of Products
Hardware cost of products sold consists primarily of costs associated with building and customization of MedCenters sold to third-party customers.

Service Costs

Service costs consists primarily of installation, integration, relocation, consumable, and maintenance cost of MedCenters at third-party customer locations, as well as related hosting and software costs.

Six Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
(in thousands)
Hardware cost of products sold:
Hardware$314 $232 $82 35 %
Depreciation62 69 (7)(10)%
Total Hardware cost of products sold376 301 75 25 %
Service costs:
Professional services21 23 (2)(9)%
Maintenance and support services101 94 7 7 %
Installation services92 49 43 88 %
Total service costs214 166 48 29 %
Total cost of products sold and services$590 $467 $123 26 %
During the six months ended June 30, 2023, hardware cost of products sold increased $75 thousand to $376 thousand compared to the same period in 2022. The $75 thousand increase was primarily due to an increase in hardware costs associated with the increased number of units sold during the six months ended June 30, 2023 as compared to the same prior year period.
During the six months ended June 30, 2023, service costs increased $48 thousand to $214 thousand primarily due to increased installation costs related to the sale of more MedCenters during the six months ended June 30, 2023 as compared to the same prior year period.
General and Administrative
General and administrative expenses consist of personnel costs, facility expenses and expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and share-based compensation. Facility expenses consist of rent and other related costs specific to our corporate and technology activities. Corporate insurance, office supplies and technology expenses are also captured within general and administrative expenses. We incurred and expect to incur expenses as a result of being a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.
We have a stock option plan whereby awards are granted to certain of our employees. The fair value of the stock options and restricted stock units granted by us to our employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. We measure the fair value of the stock options using the Black-Scholes option pricing model as of the grant date. Shares issued upon the exercise of stock options and vesting of restricted stock units are new shares. We estimate forfeitures based on historical experience and expense related to awards is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are expensed.
30

Six Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
General and administrative expenses:(in thousands)
Wages and salaries$4,537 $5,496 $(959)(17)%
Professional services1,594 1,189 405 34 %
Share-based compensation999 1,176 (177)(15)%
Insurance530 872 (342)(39)%
Software licenses and support386 511 (125)(24)%
Rent, utilities, and other1,078 981 97 10 %
Office and IT supplies98 83 15 18 %
Travel and other employee expenses23 115 (92)(80)%
Depreciation of property, plant and equipment80 65 15 23 %
Total general and administrative expenses$9,325 $10,488 $(1,163)(11)%
During the six months ended June 30, 2023, general and administrative expenses decreased approximately $1.2 million to $9.3 million compared to the same period in 2022. This decrease was primarily due to reduction in wages and salaries of $959 thousand resulting from a reduced headcount due to a reduction in force during the period and decreased insurance costs of $342 thousand primarily related to decrease director and officer insurance premiums from lower negotiated rates, partially offset by a $405 thousand increase in professional services costs related to our private placement funding, audit fees and legal services due additional complex accounting issues, discontinued operations reporting requirements, and consultant support services within our finance department due to employee turnover.
Selling and Marketing
Selling and marketing expenses consist of personnel costs, marketing and advertising costs, and marketing related expenses for outside professional services. Wages and salaries consist of compensation costs incurred for all selling and marketing employees including our in clinic customer account managers, and contractors including bonuses, health plans, and severance.
Six Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
Selling and marketing expenses:(in thousands)
Wages and salaries$224 $85 $139 164 %
Travel and other employee expenses— 58 (58)(100)%
Marketing30 12 18 150 %
Total selling and marketing expenses$254 $155 $99 64 %
During the six months ended June 30, 2023, selling and marketing expenses increased approximately $99 thousand to $254 thousand compared to the same period in 2022. This increase was primarily due to a $139 thousand increase in salaries and wages is primarily due to additional increase in headcount related to the sales team, in addition to, one time severance expense paid out during the period, partially offset by a $58 thousand decrease in travel and other employee expenses due to decreased travel demands as we right size our operating cost.
Research and Development
Research and development expenses represent costs incurred to develop and innovate our MedCenter platform technology, including development work on hardware, software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs.
Six Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
Research and development expenses:(in thousands)
Wages and salaries$314 $369 $(55)(15)%
Other expenses7 108 (101)(94)%
Total research and development expenses$321 $477 $(156)(33)%
31

During the six months ended June 30, 2023, research and development expenses decreased approximately $156 thousand to $321 thousand compared to the same period in 2022. This decrease was primarily due to a decrease in headcount as a result of outsourcing research and development costs in order to reduce expenses and the completion of prior period product improvement activities.
Interest Expense
Interest expense consists of accrued interest on outstanding debt and is payable monthly.
Six Months Ended June 30,2023 vs. 2022
20232022Amount Change% Change
(in thousands)
Interest expense:
Interest expense$315 524 $(209)(40)%
Total interest expense$315 $524 $(209)(40)%
During the six months ended June 30, 2023, interest expense decreased $209 thousand to $315 thousand as compared to the same period in 2022, due to a decrease in outstanding debt during the six months ended June 30, 2023 as compared to the same period in the prior year. Total outstanding debt principal was $2.0 million as of June 30, 2023, as compared to $10.1 million as of June 30, 2022.


Liquidity and Capital Resources
Sources of Liquidity
Since inception through June 30, 2023, our operations have been financed primarily by net cash proceeds from the sale of stock and warrants from private placements, the sale of redeemable preferred stock and debt. As of June 30, 2023, we had $14.4 million in cash and cash equivalents and an accumulated deficit of $262.8 million.

2023 Pre-Funded and Series-A Warrants

On March 13, 2023, we closed a private placement of securities with certain institutional investors pursuant to the terms of a definitive securities purchase agreement, or the 2023 Purchase Agreement. The offering consisted of pre-funded warrants to purchase common stock, or the Pre-Funded Warrants issued upon closing at a price of $16.06 per underlying share and which are exercisable into shares of common stock at an exercise price of $0.05 per share, and Series A warrants to purchase common stock an exercise price of $19.27 per share, or the Series A Warrants. The issuance of the Series A Warrants (including the underlying shares of common stock) and the portion of the Pre-Funded Warrants in excess of 19.99% of the shares of Common Stock outstanding prior to the offering was subject to approval by our stockholders. At the initial closing of the offering, we received total gross proceeds of approximately $16 million, before deducting offering expenses. We intend to use the net proceeds from this offering to fund one-time costs associated with restructuring, repay outstanding debt, and finance our growth initiatives related to its MedCenter technology business.

On June 14, 2023, at our annual stockholders’ meeting, we obtained the requisite stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. We issued the Series A Warrants on June 16, 2023.

2023 SVB Warrants

On February 10,2023, as part of the First Amendment to the Loan and Security Agreement with Silicon Valley Bank (see Note 8), we issued warrants, or the SVB Warrants, to SVB to purchase up to an aggregate of 4 thousand shares of common stock at an exercise price of $16.37, with an expiration date of February 10, 2035. The number of shares and the exercise price were subject to adjustment, or the Special Adjustment for Warrant Shares, upon the occurrence of the last closing of our next equity financing, as set forth in the SVB Warrants.

On March 9, 2023, we entered into the 2023 Purchase Agreement and sold securities in a private placement at two closings that constituted our next equity financing within the meaning of the SVB Warrants. The first closing occurred on March 13, 2023 and the second closing occurred on June 16, 2023. On June 16, 2023, pursuant the Special Adjustment for Warrant Shares, the number of shares of common stock underlying the SVB Warrants increased to 5.4 thousand and the per share exercise price decreased to $10.25.

On February 10, 2022 and March 29, 2023, we entered into the First Loan Amendment and Consent, and Letter Agreement, respectively, which provides waivers of any legal action or enforcement of rights and remedies with respect to the specified defaults enumerated therein, on and prior to February 10, 2023 and March 29, 2023. As of the date of this report, we are in compliance with all covenants under the terms of our Loan Agreement.
32


2022 Warrants

In April 2022, we completed a private placement, pursuant to which we received $40.0 million in gross proceeds before deducting placement agent commissions and other offering expenses. An additional $10.0 million in gross proceeds closed on July 1, 2022. In connection with the private placement, we issued callable warrants in April 2022 and July 2022. The warrant call option is exercisable by us beginning on each of the 12-month and 24-month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of our shares. If the warrants are exercised in full immediately after issuance by the Investors, we would receive additional gross proceeds of up to $29.4 million. If we exercise our call option immediately after issuance, then we could raise approximately $19.6 million in gross proceeds.

In June, 2021 we added to our liquidity resources through a senior secured term loan facility with SVB, or the Loan Agreement, pursuant to which we borrowed $10.0 million in aggregate initial term loans. In December 2022, and February 2023, we made discretionary principal payments to reduce our senior secured term loan by $5.0 million and $3.0 million, respectively. In conjunction with the $3.0 million principal payment, an additional $0.4 million was paid related to required final payments. For more detail on outstanding debt and associated maturities, see Note 8 in our unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q and Note 13 and Note 21 in our Annual Financial Statements presented in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on April 14, 2023 and retrospectively revised and recast for discontinued operations presentation in our Current Report on Form 8-K filed with the SEC on June 29, 2023.

Management is continuously exploring additional sources of financing, the success of which is dependent on market conditions. In continued efforts to address negative impacts from the economy, and the economic uncertainties related to the conflict in Ukraine resulting from the military actions of Russia, including on the global economy, interest rate fluctuations, inflationary pressures and our supply chain, management is looking to others financial strategies such a stock splits and warrant exercise, should market conditions allow. Given our recent private placement and reduction in operating cost due to the disposition of our retail pharmacy services business, management believes there is no substantial doubt about our ability to continue as a going concern within 12 months from the date of issuance of the financial statements.

Furthermore, if we issue equity securities to raise additional funds, our existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of our existing stockholders. Failure to raise capital, however, as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Our management actively evaluates matters of liquidity and growth capital needs, including evaluating debt and equity as sources of growth capital with a focus on lower overall weighted average cost of capital and favorable financing terms. Our primary uses of liquidity are operating activities, capital expenditures, and lease payments.

SVB and SVB Successor

On March 10, 2023, SVB, based in Santa Clara, California, was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. On March 10, 2023, the Federal Deposit Insurance Corporation (the “FDIC”) took control of SVB and created the National Bank of Santa Clara to hold the deposits of SVB after SVB was unable to continue their operations. SVB’s deposits are insured by the FDIC in amount up to $250 thousand for any depositor and any deposit in excess of this insured amount could be lost. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all deposited funds starting March 13, 2023.

On March 13, 2023, the Company was informed by SVB that the Company was still bound by the terms, conditions, and covenants of the Company’s Loan and Security Agreement with SVB, or the Loan Agreement, and the Loan Amendment and Consent. On March 29, 2023, the Company entered into a Letter Agreement, or Letter Agreement, with each of (a) Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB Successor, in its capacity as administrative agent and collateral agent, (b) SVB Successor, as a lender, and (c) SVB Innovation Credit Fund VIII, L.P., or SVB Capital, as a lender, and obtained a waiver for any event of default occurring prior to March 29, 2023, to include the year ended December 31, 2022. The Letter Agreement also amends the Loan Agreement to provide that the Company is only required to maintain on deposit at SVB Successor or its affiliates, at least 50% of the aggregate dollar value of all of the Company accounts at all financial institutions.

As of March 31, 2023, we had approximately $9.7 million on deposit with SVB successor and $5.3 million on deposit with another financial institution. We do not anticipate a material impact on our financial condition, operations or Loan and Security Agreement with SVB. We continue to monitor the circumstances surrounding SVB. As of the date of this filing we have full access to and control over all our cash and, cash equivalents across all financial institutions.

33

Cash Flows
The following table summarizes our cash flows for the six months ended June 30, 2023 and 2022:
Six Months Ended June 30,
2023 vs. 2022
(In thousands)20232022Amount Change% Change
Cash used in operating activities$(9,589)$(25,714)$16,125 (63)%
Cash used in investing activities(58)(1,726)1,668 (97)%
Cash provided by financing activities12,562 37,229 (24,667)(66)%
Net increase in cash and cash equivalents, and restricted cash$2,915 $9,789 $(6,874)(70)%
Operating Activities
During the six months ended June 30, 2023, cash used in operating activities decreased $16.1 million to $9.6 million compared to the same period in 2022. The decrease in cash used in operating activities was primarily due to exiting the pharmacy services business in January 2023, with reduced operating activities during the six months ended June 30, 2023, as compared to the same period in the prior year.
Investing Activities
During the six months ended June 30, 2023, cash used in investing activities decreased $1.7 million to $58 thousand compared to the same period in 2022. The decrease during the six months ended June 30, 2023 was primarily due to an decrease in investment in property, plant and equipment and intangible software assets as compared to the same prior year period primarily due to the strategic shift in business and management of capital investment.
Financing Activities
During the six months ended June 30, 2023, cash provided by financing activities decreased $24.7 million to compared to the same period in 2022. The decrease is primarily due to our private placement in April 2022 and the receipt of $40.0 million in gross proceeds before deducting placement agent commissions and other offering expenses during the six months ended June 30, 2022, coupled with a $3.0 million payment on our senior secured term loan with SVB during the six months ended June 30, 2023. Partially offsetting the decreases noted above, during the six months ended June 30, 2023, we received $16.0 million in gross proceeds before deducting placement agent commissions and other offering expenses from the sale of Pre-Funded Warrants and Series A Warrants.

Cash Flows Related to Discontinued Operations

As a result of our exit from the pharmacy services business, we met the requirements of ASC 205-20 to report the results of the pharmacy services business as a discontinued operation. Accordingly, the cash flows from discontinued operations are as noted below and within these condensed consolidated financial statements.

Cash used by operating activities by the pharmacy services business totaled $987 thousand and $14.4 million for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash provided by (used in) investing activities from the pharmacy services business totaled $212 thousand and $(428) thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash used in financing activities from the pharmacy services business totaled $47 thousand and $41 thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. Depreciation and amortization expense of the pharmacy services business totaled $895 thousand and $673 thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. The condensed consolidated statements of cash flows included $319 thousand loss on disposal of net assets from discontinued operations, which comprised of losses related to net realizable value adjustments to right of use assets related to leases and prepaid assets, and abandonment of certain property, plant, and equipment related to our discontinued operations.

Critical Accounting Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We believe that the estimates, assumptions and judgments involved in the accounting policies described below have the greatest potential impact on our consolidated financial statements and, therefore, we consider these to be our critical accounting estimates. Accordingly, we evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. Please refer to Note 4 in our consolidated financial statements included in Item 8 of our Annual Report on Form 10-K for information about our significant accounting policies, and Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31,
34

2022, filed with the SEC on April 14, 2023, and retrospectively revised and recast for discontinued operations in our Current Report on Form 8-K filed with the SEC on June 29, 2023.

Critical Estimates in Applying the Company’s Accounting Policies

Derivative Warrant Liabilities

The Pre-Funded Warrants and Series A Warrants initially did not meet the equity classification requirements under ASC 815 - Derivative and Hedging; specifically we did not have a sufficient amount of Common Stock available to be issued to settle the warrants upon grant and through June 14, 2023, due to the Nasdaq 19.99% cap that limited our ability to issue Common Stock to settle the Series A Warrants and Pre-funded Warrants. Consequently, the Pre-Funded Warrants and Series A Warrants were classified as liabilities and therefore measured at fair value. Subsequent to its grant date fair value measurement, and through the date of June 14, 2023, we remeasured the warrants at fair value and recognized a gain from change in fair value of warrants on the statement of operations and comprehensive loss. On June 14, 2023, at our annual stockholder meeting, we obtained the requisite stockholder approval for the removal of the exercise cap and for the issuance of the Series A Warrants. Subsequent to the remeasurement of the Pre-Funded Warrants and the Series A Warrants, as noted above, the Company reassessed the liability classification due to receipt of the requisite stockholder approvals on June 14, 2023. We determined the Pre-Funded Warrants and Series A Warrants met the equity classification requirements and the warrants were re-classified from liability to equity as of June 14, 2023.

We used the Black-Scholes option pricing model to estimate fair value of these warrants at issuance and at each exercise and period end date. The key assumptions used in the model are the expected future volatility in the price of our shares, exercise price of the warrants, risk free rates relative to the expected life of the warrants, and the expected life of the warrants. The impact of changes in key assumptions as described see Part I, Item I, Note 12 in this report of our unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see Part II, Item 8, Note 5 of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on April 14, 2023 and retrospectively revised and recast for discontinued operations in our Current Report on Form 8-K filed with the SEC on June 29, 2023, and Note 4, “Recent Accounting Pronouncements,” in the notes to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

35

Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2023, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of June 30, 2023, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2023, our disclosure controls and procedures were not effective because of the material weakness in our internal control over financial reporting described below.

Material Weakness

In connection with the preparation of our Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, our management identified the following material weakness in our internal control over financial reporting that caused management to conclude that, as of December 31, 2022 and March 31, 2023, our disclosure controls and procedures were not effective:

•Our initial supporting documentation for certain technical accounting matters did not adequately address the appropriate accounting guidance, which was indicative of a lack of controls relating to our financial reporting process, including the evaluation and analysis of accounting treatment for complex, non-standard transactions.

We recognize the importance of the control environment. Consequently, we are designing and implementing remediation measures to address the material weakness and enhance our internal control over financial reporting. During the second quarter of 2023, to enhance our internal control over financial reporting, management took the following actions:

•We designed and implemented additional controls relating to (i) the preparation of initial supporting documentation for certain technical accounting matters in order to adequately address the appropriate accounting guidance, including the evaluation and analysis of accounting treatment for complex, non-standard transactions, and (ii) the engagement of a national consulting firm with the appropriate skill set to support and assist in our evaluation and accounting of complex, non-standard transactions.

We believe the actions described above will be sufficient to remediate over time the identified material weakness and strengthen our internal control over financial reporting. However, the new and enhanced controls have not operated for a sufficient amount of time to conclude that the material weakness has been remediated. Notwithstanding, as of June 30, 2023, we believe our condensed consolidated financial statements included in this report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States. However, the elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these actions will ultimately have the intended effects. We will continue to monitor the effectiveness of these controls and will make any further changes management determines appropriate.

Changes in Internal Control Over Financial Reporting

During the quarter ended June 30, 2023, we made changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) as part of our efforts to remediate the material weakness in such controls that we identified in connection with the preparation of our Annual Report on Form 10-K for the year ended December 31, 2022, and our Quarterly Report on Form 10-Q for the three months ended March 31, 2023, as described above in this Item 4.

Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
36

PART II
Item 1. Legal Proceedings
The information set forth under the heading “Legal” in Note 10, Commitments and Contingencies, in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.

Item 1A. Risk Factors
Except as set forth below, there have been no material changes to the risk factors disclosed in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022, or the 2022 Annual Report, filed with the Securities and Exchange Commission on April 14, 2023. The risk factors described in our 2022 Annual Report, as well as other information set forth in this Quarterly Report on Form 10-Q, could materially adversely affect our business, financial condition, results of operations and prospects, and should be carefully considered. The risks and uncertainties that we face, however, are not limited to those described in the 2022 Annual Report. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business and the trading price of our securities.

Our ability to continue operations or to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from Nasdaq for failing to comply with its continued listing requirements.

On October 31, 2022, we received a deficiency letter from Nasdaq notifying us that for the prior 30 consecutive business days the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had 180 calendar days starting on October 31, 2022, or until May 1, 2023, to regain compliance with the Bid Price Rule. On May 2, 2023, Nasdaq informed us of its decision to extend the period for us to regain compliance with the Bid Price Rule by an additional 180 calendar days, or until October 30, 2023. If, at any time before October 30, 2023, the bid price for our common stock closes at $1.00 or more for a minimum of 10 consecutive business days, we will regain compliance with the Bid Price Rule, unless the Nasdaq staff exercises its discretion to extend this 10-day period pursuant to Nasdaq listing rules. We have not regained compliance with Nasdaq Listing Rules as of the filing date of this Quarterly Report on Form 10-Q.

To regain compliance with the Bid Price Rule, we implemented a reverse stock split of our common stock at a ratio of 1-for-50, which reverse stock split became effective at 5:00 p.m. Eastern time on July 31, 2023. Our common stock commenced trading on the Nasdaq Capital Market on the post-split basis on August 1, 2023, and the bid price for our common stock has closed above $1.00 each business day since the reverse stock split became effective. We expect to regain compliance with the Bid Price Rule at the close of trading on August 14, 2023, unless the Nasdaq staff exercises its discretion to extend the 10-day trading period. The reverse stock split could result in an adverse effect on or negatively impact the price of our common stock.

If we do not regain compliance with the Bid Price Rule, or if the bid price for our common stock again closes below the minimum $1.00 per share for 30 consecutive business days in violation of the Bid Price Rule, our common stock may be delisted from Nasdaq. Additionally, even if we regain compliance with and continue to satisfy the Bid Price Rule, there can be no assurance that we will maintain compliance with the other requirements for listing our common stock on Nasdaq.

Delisting could adversely affect our ability to raise additional capital through the public or private sale of equity securities, and could significantly affect the ability of investors to trade our securities, which would negatively affect the value and liquidity of our common stock.

We and our stockholders could be materially adversely impacted if our common stock is delisted from Nasdaq. In particular:

•we may lose the confidence of our current or prospective third-party providers and collaboration partners, which could jeopardize our ability to enter into supply, manufacturing, licensing, and collaboration agreements and continue our business as currently conducted;
•we could be in a material breach under agreements we have with third parties, such as the Loan and Security Agreement between us and Silicon Valley Bank;
•the price of our common stock will likely decrease;
•stockholders may be unable to sell or purchase our common stock when they wish to do so;
•the potential loss of confidence by employees;
•we may lose the interest of institutional investors in our common stock;
•we may have fewer business development opportunities;
•we may lose the interest of institutional investors in our common stock;
37

•we may have fewer business development opportunities;
•we may lose media and analyst coverage;
•our common stock could be considered a “penny stock,’ which would likely limit the level of trading activity in the secondary market for our common stock; and
•we would likely lose the active trading market for our common stock, as it may only be traded on one of the over-the counter markets, if at all.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.

Item 3. Defaults Upon Senior Securities
None.

Item 4. Mine Safety Disclosures
None.

Item 5. Other Information
None.
38

Item 6. Exhibits
Incorporated by Reference
Exhibit NumberDescriptionFormExhibitFiling Date
3.18-K3.1June 16, 2022
3.28-K3.1July 31, 2023
3.3Amended and Restated Bylaws of MedAvail Holdings, Inc.8-K3.2November 18, 2020
4.1Form of Warrant8-K10.3April 4, 2022
4.28-K10.3March 14, 2023
4.38-K10.4March 14, 2023
4.48-K10.2February 16, 2023
4.58-K10.3February 16, 2023
31.1*
31.2*
32.1**
101*Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q
104*Inline XBRL for the cover page of this Quarterly on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set

* Filed herewith.
** Furnished herewith.
39

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.


MEDAVAIL HOLDINGS, INC.
Dated: August 14, 2023By:/s/ Mark Doerr
 Mark Doerr
 President and Chief Executive Officer
(Principal Executive Officer)
By:/s/ Ramona Seabaugh
Ramona Seabaugh
Chief Financial Officer
(Principal Financial and Accounting Officer)


40

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
Pursuant to
Securities Exchange Act Rules 13a-14(a) and 15d-14(a),
As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Mark Doerr, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of MedAvail Holdings, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: August 14, 2023By:
/s/ Mark Doerr
 Mark Doerr
 President, Chief Executive Officer
(Principal Executive Officer)



CERTIFICATION OF CHIEF FINANCIAL OFFICER
Pursuant to
Securities Exchange Act Rules 13a-14(a) and 15d-14(a),
As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Ramona Seabaugh, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of MedAvail Holdings, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: August 14, 2023By:
/s/ Ramona Seabaugh
 Ramona Seabaugh
 Chief Financial Officer
(Principal Financial and Accounting Officer)


Exhibit 32.1
CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of MedAvail Holdings, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Mark Doerr, as Chief Executive Officer of the Company, and Ramona Seabaugh, as Chief Financial Officer, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
1.The Report, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2023By:

/s/ Mark Doerr



President and Chief Executive Officer



(Principal Executive Officer)

By:

/s/ Ramona Seabaugh


Chief Financial Officer



(Principal Financial and Accounting Officer)

v3.23.2
Cover - shares
 6 Months Ended
Jun. 30, 2023
Aug. 08, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-36533  
Entity Registrant Name MEDAVAIL HOLDINGS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 90-0772394  
Entity Address, Address Line One 4720 East Cotton Gin Loop,  
Entity Address, Address Line Two Suite 220  
Entity Address, City or Town Phoenix,  
Entity Address, State or Province AZ  
Entity Address, Postal Zip Code 85040  
City Area Code 877  
Local Phone Number 830-0826  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol MDVL  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   1,613,911
Entity Central Index Key 0001402479  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment flag false  
Document Period End Date --12-31  
v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 14,359 $ 11,444
Restricted cash 676 676
Accounts receivable 292 404
Inventories 10,065 8,817
Prepaid expenses and other current assets 711 2,569
Current assets from discontinued operations 946 4,842
Total current assets 27,049 28,752
Property, plant and equipment, net 732 438
Intangible assets, net 657 451
Right-of-use assets 701 624
Other assets 40 30
Long-term assets from discontinued operations 729 2,837
Total assets 29,908 33,132
Current liabilities:    
Accounts payable 796 818
Accrued liabilities 462 552
Accrued payroll and benefits 832 1,379
Deferred revenue 346 152
Current portion of lease obligations 208 246
Current liabilities from discontinued operations 1,512 2,794
Total current liabilities 4,156 5,941
Long-term debt, net 1,506 4,798
Long-term portion of lease obligations 550 441
Long-term liabilities from discontinued operations 651 1,128
Total liabilities 6,863 12,308
Commitments and contingencies (Note 10)
Stockholders' equity:    
Common shares ($0.001 par value, 300,000,000 shares authorized, 1,613,870 and 1,603,394 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively) [1] 2 2
Warrants 35,480 11,148
Additional paid-in-capital 257,318 256,308
Accumulated other comprehensive loss (6,928) (6,928)
Accumulated deficit (262,827) (239,706)
Total stockholders' equity 23,045 20,824
Total liabilities and stockholders' equity $ 29,908 $ 33,132
[1] Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
v3.23.2
Condensed Consolidated Balance Sheets (Parenthetical)
Jun. 30, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Statement of Financial Position [Abstract]    
Common shares, par value (in USD per share) | $ / shares [1] $ 0.001 $ 0.001
Common shares, authorized (in shares) [1] 300,000,000 300,000,000
Common shares, issued (in shares) [1] 1,613,870 1,603,394
Common shares, outstanding (in shares) [1] 1,613,870 1,603,394
[1] Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:        
Total revenue $ 405 $ 543 $ 1,025 $ 808
Cost of products sold and services:        
Total cost of products sold and services 227 336 590 467
Other operating expenses:        
General and administrative 4,365 5,053 9,325 10,488
Selling and marketing 122 55 254 155
Research and development 145 219 321 477
Total operating expense 4,632 5,327 9,900 11,120
Operating loss (4,454) (5,120) (9,465) (10,779)
Loss on issuance of warrants 0 0 (10,424) 0
(Loss) gain from change in fair value of warrant liabilities (896) 0 2,149 0
Interest income 0 0 1 1
Interest expense (146) (273) (315) (524)
Loss before income taxes (5,496) (5,393) (18,054) (11,302)
Income tax expense 0 (24) 0 (24)
Net loss and comprehensive loss from continued operations (5,496) (5,417) (18,054) (11,326)
Discontinued operations:        
Loss from discontinued operations (295) (6,301) (5,067) (13,414)
Net loss $ (5,791) $ (11,718) $ (23,121) $ (24,740)
Basic and diluted net loss per share:        
Loss from continued operations - basic (in USD per share) [1] $ (3.06) $ (3.91) $ (10.61) $ (11.05)
Loss from continued operations - diluted (in USD per share) [1] (3.06) (3.91) (10.61) (11.05)
Loss from discontinued operations - basic (in USD per share) [1] (0.16) (4.54) (2.98) (13.09)
Loss from discontinued operations - diluted (in USD per share) [1] $ (0.16) $ (4.54) $ (2.98) $ (13.09)
Weighted average shares outstanding - basic (in shares) [1] 1,798,245 1,387,134 1,702,360 1,024,800
Weighted average shares outstanding - diluted (in shares) [1] 1,798,245 1,387,134 1,702,360 1,024,800
Hardware and subscription revenue        
Revenue:        
Total revenue $ 127 $ 289 $ 431 $ 454
Cost of products sold and services:        
Total cost of products sold and services 131 221 376 301
Service revenue        
Revenue:        
Total revenue 278 254 594 354
Cost of products sold and services:        
Total cost of products sold and services $ 96 $ 115 $ 214 $ 166
[1] Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)
Jul. 31, 2023
Jul. 14, 2023
Jun. 14, 2023
Stock split, conversion ratio     0.0200
Subsequent Event      
Stock split, conversion ratio 0.0200 0.0200  
v3.23.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Private Placement
Common Shares
Common Shares
Private Placement
Warrants
Warrants
Private Placement
Additional Paid-in-Capital
 [1]
Accumulated Deficit
Accumulated Other Comprehensive Loss
Balance at beginning of period (in shares) at Dec. 31, 2021 [1]     658,041            
Balance at beginning of period at Dec. 31, 2021 $ 19,073   $ 0 [1]   $ 1,373   $ 216,718 $ (192,090) $ (6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (24,740)             (24,740)  
Issuance of common shares (in shares) [1]     752,941 137          
Issuance of common shares 37,201   $ 1 [1]       37,200    
Issuance of warrants         7,503   (7,503)    
Issuance of common shares under employee stock purchase plan (in shares) [1]     1,080            
Issuance of common shares under employee stock purchase plan 77           77    
Share-based compensation 1,176           1,176    
Balance at end of period (in shares) at Jun. 30, 2022 [1]     1,412,199            
Balance at end of period at Jun. 30, 2022 32,787   $ 1 [1]   8,876   247,668 (216,830) (6,928)
Balance at beginning of period (in shares) at Mar. 31, 2022 [1]     658,178            
Balance at beginning of period at Mar. 31, 2022 6,615   $ 0 [1]   1,373   217,282 (205,112) (6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (11,718)             (11,718)  
Issuance of common shares (in shares) [1]     752,941            
Issuance of common shares 37,201   $ 1 [1]       37,200    
Issuance of warrants 0       7,503   (7,503)    
Issuance of common shares under employee stock purchase plan (in shares) [1]     1,080            
Issuance of common shares under employee stock purchase plan 77           77    
Share-based compensation 612           612    
Balance at end of period (in shares) at Jun. 30, 2022 [1]     1,412,199            
Balance at end of period at Jun. 30, 2022 $ 32,787   $ 1 [1]   8,876   247,668 (216,830) (6,928)
Balance at beginning of period (in shares) at Dec. 31, 2022 1,603,394 [2]   1,603,394 [1]            
Balance at beginning of period at Dec. 31, 2022 $ 20,824   $ 2 [1]   11,148   256,308 (239,706) (6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (23,121)             (23,121)  
Issuance of common shares   $ 24,332       $ 24,332      
Shares issued for vested RSUs (in shares) [1]     9,702            
Issuance of common shares under employee stock purchase plan (in shares) [1]     774            
Issuance of common shares under employee stock purchase plan 11           11    
Share-based compensation $ 999           999    
Balance at end of period (in shares) at Jun. 30, 2023 1,613,870 [2]   1,613,870 [1]            
Balance at end of period at Jun. 30, 2023 $ 23,045   $ 2 [1]   35,480   257,318 (262,827) (6,928)
Balance at beginning of period (in shares) at Mar. 31, 2023 [1]     1,609,613            
Balance at beginning of period at Mar. 31, 2023 4,169   $ 2 [1]   11,205   256,926 (257,036) (6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (5,791)             (5,791)  
Issuance of common shares   $ 24,275       $ 24,275      
Shares issued for vested RSUs (in shares) [1]     3,483            
Issuance of common shares under employee stock purchase plan (in shares) [1]     774            
Issuance of common shares under employee stock purchase plan 11           11    
Share-based compensation $ 381           381    
Balance at end of period (in shares) at Jun. 30, 2023 1,613,870 [2]   1,613,870 [1]            
Balance at end of period at Jun. 30, 2023 $ 23,045   $ 2 [1]   $ 35,480   $ 257,318 $ (262,827) $ (6,928)
[1] Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
[2] Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
v3.23.2
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)
Jul. 31, 2023
Jul. 14, 2023
Jun. 14, 2023
Stock split, conversion ratio     0.0200
Subsequent Event      
Stock split, conversion ratio 0.0200 0.0200  
v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (23,121) $ (24,740)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of property, plant, and equipment 729 573
Amortization of intangible assets 68 295
Amortization of leased assets 518 384
Loss on disposal of net assets from discontinued operations 319 0
Loss on issuance of warrants 10,424 0
Gain from change in fair value of warrants (2,149) 0
Credit losses on accounts receivable 91 59
Term loan discount amortization and interest accretion on debt 146 141
Share-based compensation expense 999 1,176
Changes in operating assets and liabilities:    
Accounts receivable 880 (946)
Inventory 1,585 (2,380)
Prepaid expenses and other current assets 1,952 (1,185)
Accounts payable (868) 700
Accrued liabilities 223 166
Accrued payroll and benefits (1,300) 314
Deferred revenue 194 8
Operating lease liability due to cash payments (279) (279)
Net cash used in operating activities (9,589) (25,714)
Cash flows from investing activities:    
Purchase of property, plant and equipment 0 (634)
Return (payment) of security deposits 51 (5)
Purchase of intangible assets and other assets (109) (1,087)
Net cash used in investing activities (58) (1,726)
Cash flows from financing activities:    
Proceeds from issuance of warrants in private placement 15,999 37,201
Issuance of common shares upon exercise of employee stock purchase plan 11 77
Payment of debt issuance costs (380) 0
Repayment of debt (3,000) 0
Payments on finance lease obligations (68) (49)
Net cash provided by financing activities 12,562 37,229
Net increase in cash, cash equivalents and restricted cash 2,915 9,789
Cash, cash equivalents and restricted cash at beginning of period 12,120 20,089
Cash, cash equivalents and restricted cash at end of period 15,035 29,878
Supplemental cash flow information:    
Cash paid for interest 242 376
Supplemental noncash investing and financing activities:    
Inventory transferred to property, plant and equipment 0 676
Purchase of property, plant and equipment in accounts payable 0 62
Purchases of intangible assets in accounts payable 151 0
Fair value of warrant issued upon closing of private placement 0 7,503
Reclassification of warrants from liability to equity classified 24,332 0
Lease liabilities arising from obtaining right of use assets:    
Operating leases 0 206
Finance leases $ 230 $ 73
v3.23.2
NATURE OF OPERATIONS
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS NATURE OF OPERATIONS
MedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter also has the ability to facilitate live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control.
Exit of Pharmacy Services and SpotRx
On January 19, 2023, the Company announced a plan to exit the pharmacy services business to focus on its pharmacy technology business. In connection with its decision to exit the pharmacy services business, the Company initiated a reduction in force, in which employees of the pharmacy services business, representing at that time approximately 75% of the Company’s full-time employees, were terminated, effective January 18, 2023. The Company initiated the reduction in force to preserve capital and use its limited resources to pursue the pharmacy technology business.

On January 20, 2023, the Company entered into an Asset Purchase and Sale Agreement, as amended, with German Dobson CVS, L.L.C., Garfield Beach CVS, L.L.C., Longs Drug Stores California, L.L.C., Woodward Detroit CVS, L.L.C. and Holiday CVS, L.L.C., or CVS, pursuant to which the Company agreed to sell to CVS certain assets, including pharmacy records, and inventory from SpotRx pharmacies located in Tucson and Phoenix, Arizona; Buena Park, Laguna Hills and San Fernando, California; Southfield, Michigan; and in Orlando and Tampa, Florida. The transaction closed on February 9, 2023, for a final purchase price of $2.9 million (subject to $0.1 million in fees and a $0.2 million indemnification holdback). Upon closing, the pharmacy assets purchased by CVS were transferred from the SpotRx pharmacies to nearby CVS pharmacy locations.

Prior to the change in reporting for discontinued operations, the pharmacy services business comprised approximately 97% of the Company’s total revenues for the year ended December 31, 2022, and inventory from SpotRx pharmacies comprised approximately $3.0 million, or 9%, of total consolidated assets as of December 31, 2022. Pharmacy service business assets that were not sold to CVS have been or are expected to be primarily reabsorbed, settled, sold or abandoned. As of March 31, 2023, the Company had substantially completed its exit from the pharmacy services business.

The accounting requirements for reporting the pharmacy services business as a discontinued operation were met during the three months ended March 31, 2023. Accordingly, the condensed consolidated financial statements and notes to the condensed consolidated financial statements reflect the results of the pharmacy service business as a discontinued operation for the periods presented. See Note 13 for additional information.

Reverse Stock Split
On June 14, 2023, the stockholders of the Company approved resolutions to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, par value $0.001 per share, at a specific ratio within a range of 1-for-30 to 1-for-80, with the specific ratio to be determined by the Board of Directors in its sole discretion without further stockholder approval (the “Reverse Stock Split”). On July 14, 2023, the Board of Directors approved a Reverse Stock Split ratio of 1-for-50, such that every 50 shares of the Company’s common stock was combined into one share of common stock, effective at 5:00 p.m. Eastern Time on July 31, 2023. Except as otherwise noted, all references to common stock, preferred stock, restricted stock units, stock options, and warrants and all per share information throughout this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the Reverse Stock Split.
v3.23.2
LIQUIDITY
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
LIQUIDITY LIQUIDITY
The condensed consolidated financial statements for the three and six months ended June 30, 2023 and as of December 31, 2022, were prepared on the basis of a going concern which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business.

On March 9, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors, or the Investors, for the private placement of securities. Upon close of the transaction, the Company received gross proceeds from the offering of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from this offering to fund one-time costs
associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. Pursuant to the offering, on March 13, 2023, the Company issued pre-funded warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.001 per share, or Pre-Funded Warrants, and on June 16, 2023, the Company issued Series A warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.38544 per share, or Series A Warrants. See Note 13.

As of June 30, 2023, the Company had $15.0 million in cash and cash equivalents and restricted cash, and an accumulated deficit of $262.8 million. Furthermore, net cash used in operating activities for the six months ended June 30, 2023 and 2022 was $9.6 million and $25.7 million, respectively. Since inception through June 30, 2023, the Company has continually incurred losses from its operations, which have been financed primarily from net cash proceeds from sales of common stock and warrants in private placements, sales of redeemable preferred stock and debt.

Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the Company’s ability to continue as a going concern. If substantial doubt does exist, management should determine if there are plans in place which alleviate that doubt. As of December 31, 2021, and through the nine months ended September 30, 2022, the Company had identified substantial doubt as to the Company’s ability to continue as a going concern. As of December 31, 2022, there was no substantial doubt as to the Company's ability to continue as a going concern. During the first quarter of 2023, the Company raised capital in a private placement and reduced operating costs by exiting its pharmacy services business. As a result, after considering the Company's ongoing cash requirements to fund operations, management determined that the Company has sufficient financial resources to continue operations for one year from the date of issuance of these financial statements, with no substantial doubt as to the Company’s ability to continue as a going concern.
v3.23.2
BASIS OF PRESENTATION
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information, and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements.
The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. The Company's critical accounting policies are those that are both most important to its financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company is not aware of any events or circumstances which would require update to its estimates or judgements as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2022 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or SEC, on April 14, 2023 and retrospectively revised and recast for discontinued operation presentation in the Company's Current Report on Form 8-K filed with the SEC on June 29, 2023.
Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

As noted in Note 1, the Company substantially completed its exit from the pharmacy services business as of March 31, 2023. As a result, the Company has reported the operating results of its pharmacy services business in the loss from discontinued operations line in the condensed consolidated statements of operations for all periods presented. In addition, related assets and liabilities were reported as assets of discontinued operations and liabilities of discontinued operations in the condensed consolidated balance sheets for all periods presented. Unless otherwise noted, the discussion within these notes to the condensed consolidated financial statements relates to continuing operations comprised of the pharmacy technology business. See Note 13 for additional information on discontinued operations.
v3.23.2
RECENT ACCOUNTING PRONOUNCEMENTS
 6 Months Ended
Jun. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS
Recently Issued Accounting Standards Not Yet Adopted

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions
In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, or ASU 2022-03. The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements.

There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated financial statements through the reporting date.

Recently Adopted Accounting Standards

Measurement of Credit Losses on Financial Statements
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments”, or ASU 2016-13, supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, or ASU 2018-19. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, and for fiscal years beginning after December 15, 2022 for all other public business entities and private companies, with early adoption permitted. Effective January 1, 2023, the Company adopted ASU No. 2016-13. The impact of adoption of ASU 2016-13 was not material to its consolidated financial statements.
v3.23.2
LOSS PER SHARE
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
LOSS PER SHARE LOSS PER SHARE
Basic loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.
The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding. After these warrants are exercised, the related issued and outstanding common shares are included in weighted average shares outstanding:

SharesIssuance DateExercise Date
386November 18, 2020Outstanding
996,264March 9, 2023Outstanding
During the three and six months ended June 30, 2023 and 2022, there was no dilutive effect from stock options, restricted stock units, or other warrants due to the Company’s net loss position. As of June 30, 2023 and 2022, there were 1.6 million and 94 thousand shares of dilutive common stock, respectively, from underlying outstanding options, RSUs and issued warrants that were not included in the diluted shares calculation because their inclusion would have been antidilutive.
v3.23.2
FAIR VALUE MEASUREMENTS
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
Fair value measurements are categorized in one of the following three levels based on the lowest level input that is significant to the fair value measurement in its entirety:
Level 1 - Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than quoted prices in active markets for identical assets or liabilities include:
a.quoted prices for similar assets or liabilities in active markets;
b.quoted prices for identical or similar assets or liabilities in inactive markets;
c.inputs other than quoted prices that are observable for the asset or liability;
d.inputs that are derived principally from or corroborated by observable market data by correlation or other means.
If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
Level 3- Inputs to the valuation methodology are unobservable (i.e., supported by little or no market activity) and significant to the fair value measure.
As of June 30, 2023 and December 31, 2022, there were no assets and liabilities accounted for at fair value on a reoccurring basis. However,on March 9, 2023, the Company entered into a Securities Purchase Agreement, or 2023 Purchase Agreement, with certain investors. Pursuant to the 2023 Purchase Agreement, the Company agreed to issue Pre-Funded Warrants and Series A Warrants. Consequently, the Company initially identified these warrants as liabilities and measured them at fair value on March 13, 2023, and subsequently remeasured the fair value of these warrant liabilities through June 14, 2023. The Company utilized the Black Scholes valuation methodology to determine the fair value of these warrants. The fair value of these warrants was classified as Level 3 with key Level 3 inputs of exercise price, term, and volatility. Any related loss or gain on the change in fair value of these warrant liabilities was recorded in the "Loss on issuance of warrants" and "(Loss) gain in change in fair value of warrant liabilities" line items within the condensed consolidated statements of operations and comprehensive loss. On June 14, 2023, the Company evaluated these warrant liabilities for equity criteria classification and consequently reclassified these warrant liabilities to equity. See Note 12, for further details regarding the Company's Pre-Funded and Series-A Warrants, the fair value measurement of these Warrants and subsequent equity classification.
The following table presents the changes in the fair value of the Pre-Funded and Series A Warrants during the six months ended June 30, 2023:
(in thousands)Pre-Funded Warrant
Liability		Series-A Warrant
Liability		Loss on Issuance of WarrantsGain from Change in Fair Value of Warrant Liabilities
Measurement at March 13, 2023$15,940 $10,484 $(10,424)$— 
Change in fair value$(996)$(1,153)— 2,149 
Measurement at June 14, 2023$14,944 $9,331 
The Company's carrying amount of cash and cash equivalents and restricted cash approximates fair value.
v3.23.2
BALANCE SHEET AND OTHER INFORMATION
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BALANCE SHEET AND OTHER INFORMATION BALANCE SHEET AND OTHER INFORMATION
Restricted Cash
The Company considers cash to be restricted when withdrawal or general use is legally restricted. In 2021 pursuant to a Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.7 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in cash and cash equivalents presented in the condensed consolidated statements of cash flows.
Accounts Receivable
Accounts receivable are primarily comprised of trade receivables presented net of allowance for doubtful accounts when estimable and present. The Company maintains an allowance for doubtful accounts based on its assessment of the collectability of amounts owed by customers. The allowance consists of known specific troubled accounts as well as an amount based on overall estimated potential uncollectible accounts receivable based on historical experience. As of June 30, 2023 and December 31, 2022, based upon its historical collections experience, the Company had no credit risk balances that required the Company to reserve an allowance for doubtful accounts.

Inventories

The following table presents detail of inventory balances:
June 30,December 31,
(in thousands)20232022
Inventory:
MedCenter hardware$7,924 $8,154 
Spare parts2,141 663 
Total inventory$10,065 $8,817 
MedCenter hardware recognized in hardware cost of products sold was $103 thousand and $176 thousand during the three months ended June 30, 2023 and 2022, respectively, and $314 thousand and $232 thousand during the six months ended June 30, 2023 and 2022, respectively.

Prepaid Expenses and Other Current Assets

The following table presents prepaid expenses and other current assets balances:
June 30,December 31,
(in thousands)20232022
Prepaid expenses and other current assets:
Prepaid MedCenter inventory$— $1,359 
Prepaid insurance467 921 
Other244 289 
Total prepaid expenses and other current assets$711 $2,569 
Property, Plant and Equipment
The following tables present property, plant and equipment balances:
Estimated useful livesJune 30,December 31,
(in thousands)20232022
Property, plant and equipment:
MedCenter equipment
8 years
$1,530 $1,357 
IT equipment
1 - 3 years
2,002 1,908 
Leasehold improvementslesser of useful life or term of lease316 316 
General plant and equipment
5 - 8 years
376 373 
Office furniture and equipment
5 - 8 years
332 217 
Vehicles
5 years
36 36 
Construction-in-process5 5 
Total historical cost4,597 4,212 
Accumulated depreciation(3,865)(3,774)
Total property, plant and equipment, net$732 $438 
Depreciation expense of property and equipment was $57 thousand and $57 thousand for the three months ended June 30, 2023 and 2022, respectively, and $90 thousand and $117 thousand for the six months ended June 30, 2023 and 2022, respectively. Depreciation expense included in hardware cost of products sold was $2 thousand and $26 thousand for the three months ended June 30, 2023 and 2022, respectively, and $11 thousand and $52 thousand for the six months ended June 30, 2023 and 2022, respectively.
Intangible Assets

The following table presents intangible asset balances:
June 30,December 31,
(in thousands)20232022
Gross intangible assets:
Intellectual property$3,857 $3,857 
Software2,337 2,200 
Website and mobile application534 534 
Other123 — 
Total intangible assets6,851 6,591 
Accumulated amortization:
Intellectual property(3,857)(3,857)
Software(1,801)(1,749)
Website and mobile application(534)(534)
Other(2)— 
Total accumulated amortization(6,194)(6,140)
Total intangible assets, net$657 $451 

Amortization expense of intangible assets was $28 thousand and $20 thousand for the three months ended June 30, 2023 and 2022, respectively, and $54 thousand and $22 thousand for the six months ended June 30, 2023 and 2022, respectively, and are included in hardware cost of products sold and general and administrative operating expenses.

Lessee Leases

Balance sheet amounts for lease assets and leases liabilities are as follows:
June 30,December 31,
(in thousands)20232022
Lease Assets:
Operating$499$620
Finance2024
Total lease assets$701$624
Lease liabilities:
Operating:
Current$173 $241 
Long-term382 441 
Finance:
Current35 5 
Long-term168 — 
Total lease liabilities$758 $687 
The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows:
June 30,December 31,
20232022
Finance leases:
Weighted-average remaining lease term (years)4.50.5
Weighted-average discount rate11.5 %6.0 %
Operating leases:
Weighted-average remaining lease term (years)3.43.6
Weighted-average discount rate6.1 %7.3 %
Maturities of operating leases liabilities are as follows:
(in thousands)
Remaining period in 2023$135 
2024148 
2025152 
2026157 
202737 
Total operating lease payments629 
Less: present value discount(74)
Total operating leases$555 

Maturities of finance lease liabilities are as follows:
(in thousands)
Remaining period in 2023$29 
202458 
202558 
202658 
202758 
Total finance lease payments261 
Less: imputed interest(58)
Total finance leases$203 
Operating lease expense was $25 thousand and $126 thousand for the three months ended June 30, 2023 and 2022, respectively, and $154 thousand and $256 thousand for the six months ended June 30, 2023 and 2022, respectively.
v3.23.2
DEBT
 6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
DEBT DEBT
The following table presents debt balances:
June 30,December 31,
(in thousands)20232022
Term loan$2,002 $5,182 
Term loan issuance costs, net(496)(384)
Long-term debt, net$1,506 $4,798 
Maturities of debt liabilities are as follows:
(in thousands)
Remaining period in 2023$— 
2024668 
20251,000 
2026334 
Total debt$2,002 

Term Loan
The Term loan bears interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (12.25% at June 30, 2023). The term loan matures on April 1, 2026. The remaining principal repayment will commence on May 1, 2024 in equal monthly installments of the outstanding Loan balance through the maturity date.

First Amendment, Consent and Default Waiver to Loan and Security Agreement
On February 10, 2023, the Company entered into the First Amendment, Consent and Default Waiver to Loan and Security Agreement or the Loan Amendment and Consent, with each of Silicon Valley Bank, a California corporation, and an authorized foreign bank under the Bank Act (Canada), and SVB Innovation Credit Fund VIII, L.P., a Delaware limited partnership, or together SVB. Among other matters, the Loan Amendment and Consent provides SVB’s consent to the sale of certain assets related to the Company’s pharmacy services business pursuant to the previously announced Asset Purchase Agreement. The Loan Amendment and Consent also provides that upon the closing of the asset sale, the Company would pay SVB $3.4 million, which includes $0.4 million of the Final Payment (as defined in the Loan Amendment and Consent) and prepayment of $3.0 million of Term Loan Advances (as defined in the Loan Amendment and Consent), with SVB waiving the prepayment premium due on all Term Loan Advances prepaid by the Company prior to February 10, 2023. The Loan Amendment and Consent also includes SVB's waiver of any legal action or enforcement of rights and remedies with respect to certain specified defaults arising prior to February 10, 2023.

On February 10, 2023, in connection with the Loan Amendment and Consent, the Company issued warrants, or the SVB Warrants, to SVB for the purchase of up to an aggregate of 4 thousand shares of common stock at a per share exercise price of $16.37, with an expiration date of February 10, 2035. Pursuant to the terms of the SVB Warrants, the number of shares and the exercise price were adjusted as of June 16, 2023. See Note 12.

SVB Letter Agreement

On March 10, 2023, SVB, based in Santa Clara, California, was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. On March 10, 2023, the Federal Deposit Insurance Corporation (the “FDIC”) took control of SVB and created the National Bank of Santa Clara to hold the deposits of SVB after SVB was unable to continue their operations.

On March 13, 2023, the Company was informed by SVB that the Company was still bound by the terms, conditions, and covenants of the Company’s Loan and Security Agreement with SVB, or the Loan Agreement, and the Loan Amendment and Consent. On March 29, 2023, the Company entered into a Letter Agreement, or Letter Agreement, with each of (a) Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB Successor, in its capacity as administrative agent and collateral agent, (b) SVB Successor, as a lender, and (c) SVB Innovation Credit Fund VIII, L.P., or SVB Capital, as a lender, and obtained a waiver for any event of default occurring prior to March 29, 2023, to include the year ended December 31, 2022. The Letter Agreement also amends the Loan Agreement to provide that the Company is only required to maintain on deposit at SVB Successor or its affiliates, at least 50% of the aggregate dollar value of all of the Company accounts at all financial institutions.

As of June 30, 2023, the Company had approximately $9.7 million on deposit with SVB Successor and $5.3 million on deposit with another financial institution and was in compliance with all required covenants of the Loan Agreement. The Company continues to monitor the circumstances surrounding SVB and does not anticipate such circumstances will have a material impact on the Company's financial condition, operations, or on the Loan Agreement with SVB Successor. As of the date of filing this Quarterly Report on Form 10-Q, the Company has full access to and control over all of its cash and cash equivalents across all financial institutions.
v3.23.2
INCOME TAXES
 6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company incurred minimal income tax expense for the three months ended June 30, 2023 and 2022, due to ongoing losses and minimum state income tax obligations. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses.
As of June 30, 2023 and December 31, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.
v3.23.2
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Litigation
The Company is and, from time to time may in the future become, involved in legal proceedings, claims and litigation in the ordinary course of business. The Company has become subject to certain demands, and claims from former employees relating to the reduction in force the Company implemented in connection with the restructuring of the company and the disposition of its pharmacy services business. The Company intends to vigorously defend itself against such pending and threatened actions. The Company cannot determine a reasonable estimate of the maximum possible loss or range of loss for pending or threatened matters given that they are at various stages of the litigation process and each case is subject to the inherent uncertainties of litigation. In management’s opinion, based on currently available information, any potential loss resulting from the resolution of these matters is not expected to have a material adverse effect on the Company’s results of operations, financial position, or cash flows.
v3.23.2
SHARE-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
Share-based Compensation
The following table presents the Company's expense related to share-based compensation, in thousands:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Share-based compensation $381 $612 $999 $1,176 
Expense remaining to be recognized for unvested option awards from the 2012, 2018, 2020 and 2022 plans as of June 30, 2023, was $1.5 million, which will be recognized on a weighted average basis over the next 2.0 years. Expense remaining to be recognized for unvested RSU awards as of June 30, 2023, was $0.9 million, which will be recognized on a weighted average basis over the next 1.5 years.

The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2023:
(in thousands, except for share and per share amounts)Number of AwardsWeighted Average Exercise PriceWeighted Average Fair ValueWeighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value
Outstanding, at December 31, 202287,995 $94.64 $57.26 $— 
Granted43,637 15.25 11.66 1 
Exercised/Released— — — — 
Expired(62)622.69 372.66 — 
Forfeited(28,362)95.49 53.27 — 
Outstanding, end of period, at June 30, 2023103,208 $60.66 $39.03 9.11$— 
Vested and exercisable, at June 30, 2023 37,186 107.53 66.14 8.18— 
Vested and unvested exercisable, at June 30, 202337,186 107.53 66.14 8.18— 
Vested and expected to vest, at June 30, 2023100,542 61.91 39.79 9.09— 
The following table present outstanding RSU awards activity during the six months ended June 30, 2023:
Number of AwardsWeighted Average Exercise PriceWeighted Average Grant Date Fair ValueWeighted Average Remaining Contractual Life (Years)
Unvested outstanding, at December 31, 202247,531 $— $65.30 — 
Granted— $— $— — 
Exercised/Released(9,702)$15.84 $77.02 — 
Cancelled/Forfeited(18,983)$— $62.67 — 
Expired— $— $— — 
Unvested outstanding, at June 30, 202318,846 $— $61.99 14.29
Vested outstanding shares at June 30, 2023— $— $— — 

As of June 30, 2023 and December 31, 2022, there was an aggregate of 93 thousand and 46 thousand shares of common stock, respectively, available for grant under the 2020 Plan. As of June 30, 2023 and December 31, 2022, there was an aggregate of 22 thousand and 4 thousand shares of common stock, respectively, available for grant under the 2022 Inducement plan.
v3.23.2
WARRANTS
 6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
WARRANTS WARRANTS
The Company effected the Reverse Stock Split on July 31, 2023, pursuant to which every 50 shares of the Company’s common stock was combined into one share. The number of underlying shares and the exercise price of each of the Company’s warrants were proportionately adjusted to give effect to the Reverse Stock Split. The Reverse Stock Split had no effect on the accounting for the Company’s warrants.

2022 Warrants
On March 30, 2022, the Company entered into a Securities Purchase Agreement with certain investors. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell in a private placement, or the 2022 Private Placement, up to 942 thousand shares of the Company’s common stock and warrants, or the 2022 Warrants, to purchase up to 470 thousand shares of common stock. The securities were sold at two closings at a price per share of $50.13.

At the first closing on April 4, 2022, the Company sold 75.2 thousand shares of common stock and 2022 Warrants to purchase up to 376 thousand shares of common stock, for gross proceeds of $40.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on April 4, 2022 had a fair value of $9.2 million, a 5 year term and a per share exercise price of $62.50. A second and final closing occurred on July 1, 2022, at which the Company sold an additional 188 thousand shares of common stock and 2022 Warrants to purchase up to 94.0 thousand shares of common stock, for gross proceeds of $10.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on July 1, 2022 had a fair value of $4.5 million, a 5 year term and a per share exercise price of $62.50.

None of the 2022 Warrants have been exercised or expired as of June 30, 2023 and December 31, 2022. The 2022 Warrants meet equity classification requirements and therefore are classified in our stockholders’ equity.

2023 SVB Warrants
On February 10, 2023, as part of the First Amendment to the Loan and Security Agreement with Silicon Valley Bank ("SVB") (see Note 8), the Company issued warrants, or SVB Warrants, to purchase up to an aggregate of 4 thousand shares of common stock at a per share exercise price of $16.37, with an expiration date of February 10, 2035. The number of shares and the exercise price were subject to adjustment, or the Special Adjustment for Warrant Shares, upon the occurrence of the last closing of the Company’s next equity financing, as set forth in the SVB Warrants.

On March 9, 2023, the Company entered into the 2023 Purchase Agreement, with certain institutional investors, pursuant to which the Company sold securities in a private placement at two closings that constituted the Company’s next equity financing within the meaning of the SVB Warrants. The first closing occurred on March 13, 2023 and the second closing occurred on June 16, 2023. On June 16, 2023, pursuant the Special Adjustment for Warrant Shares, the number of shares of common stock underlying the SVB Warrants increased to 5.4 thousand and the per share exercise price decreased to $10.25.

Upon the grant date, February 10, 2023, the fair value of the SVB Warrants was approximately $57 thousand measured using the Black-Scholes option pricing model. The SVB Warrants met equity classification requirement under ASC 815 - Derivative and Hedging, specifically
due to the warrants having a limit on the number of shares the Company is required to deliver upon exercise and the warrant not including cash-settled top-off or make-whole provisions, as well as, other conditions. As such, the SVB Warrants met the equity classification requirements and are classified in the Company's stockholders' equity. None of the SVB Warrants have been exercised or expired as of June 30, 2023.

The key input assumptions utilized in the valuation of the SVB Warrants were as follows:
Grant date
Market price$16.00
Exercise price$16.37
Term (Years)12
Volatility85%
Risk Free Rate3.68%

2023 Pre-Funded and Series A Warrants
As noted above, on March 9, 2023, the Company entered into the 2023 Purchase Agreement with certain investors. Pursuant to the 2023 Purchase Agreement, the Company agreed to issue Pre-Funded Warrants and Series A Warrants. On March 13, 2023, at the first closing of the offering, the Company sold at a price of $16.06 per underlying share, Pre-Funded Warrants to purchase up to 996.3 thousand shares of common stock at an exercise price of $0.05 per share for total gross proceeds of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from the offering to fund costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. The number of Pre-Funded Warrants exercisable by investors was limited to 19.99% of the Company’s common stock outstanding immediately prior to the offering pursuant to a listing rule of The Nasdaq Stock Market, which required that the Company obtain stockholder approval of the issuance of shares above this 19.99% cap. The Pre-Funded Warrants were classified as a liability at issuance due to the need for the Company to obtain stockholder approval to settle the instruments in shares.

On March 9, 2023, the Company also agreed to issue Series A Warrants to purchase up to 996.3 thousand shares of common stock with an exercise price of $19.27 per share, which was conditional upon the Company obtaining stockholder approval of the issuance. The Series A Warrants were also classified as a liability as the Company had an irrevocable obligation to obtain stockholder approval of the issuance of the Series A Warrant, and as such did not have sufficient shares to settle the obligation and consequently failed the equity classification requirements pending shareholder approval.

On June 14, 2023, at its annual stockholders’ meeting, the Company obtained the requisite stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company issued the Series A Warrants on June 16, 2023.

Upon grant, March 13, 2023, the fair value of the Pre-Funded Warrants and Series A Warrants was $15.9 million and $10.5 million, respectively. The Company recorded the $10.4 million difference between the offering proceeds and grant date fair value as a loss on issuance of warrants in the statement of operations and comprehensive loss. Subsequent to its grant date fair value measurement, and through June 14, 2023, the Company remeasured the warrants at fair value and recognized a gain from change in fair value of warrants on the statement of operations and comprehensive loss. As of June 14, 2023, the fair value of Pre-Funded Warrants and Series A Warrants was $14.9 million and $9.3 million, respectively. For the three and six months ended June 30, 2023, the Company recognized a loss of $0.9 million and gain of $2.1 million in fair value remeasurement of the Pre-Funded Warrants and Series A Warrants, respectively.

Subsequent to the remeasurement of the Pre-Funded Warrants and Series A Warrants, the Company reassessed the liability classification of these warrants due to the Company obtaining on June 14, 2023, stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company determined that the Pre-Funded Warrants and Series A Warrants met the equity classification requirements, and the warrants were re-classified from liability to equity as of June 14, 2023.

The fair values of the Pre-Funded Warrants and Series A Warrants were measured using the Black-Scholes option pricing model. As of the grant date and June 14, 2023, the key input assumptions utilized in the valuation of the Pre-funded Warrants were as follows:
Grant dateJune 14, 2023
Market price$16.00$15.00
Exercise price$0.05$0.05
Term (Years)*IDFIDF
Volatility85%82%
Risk Free Rate3.70%3.90%
*Warrant is outstanding until fully exercised; as such, the term was measured as indefinite.

The key input assumptions utilized in the valuation of the Series A Warrants were as follows:
Grant dateJune 14, 2023
Market price$16.00$15.00
Exercise price$19.27$19.27
Term (Years)54.7
Volatility85%82%
Risk Free Rate3.68%4.10%
STOCKHOLDERS' EQUITY
Reverse Stock Split
On June 14, 2023, the stockholders of the Company approved a one-for-fifty reverse stock split of its outstanding shares of common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on July 31, 2023 (the “Effective Time”). At the Effective Time, every fifty issued and outstanding shares of the Company’s common stock were converted into one share of the Company’s common stock.

The reverse split affected all the stockholders uniformly and did not affect any stockholder’s percentage ownership interests in the Company or proportionate voting power. Each common stockholder held the same percentage of the outstanding common stock immediately following the reverse split as that stockholder did immediately before the reverse split, except for minor adjustments as a result of the treatment of fractional shares.

No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). As a result, the number of common shares outstanding was reduced from 80,693,517 immediately before the Effective Time to 1,613,870.

There was no change in the number of authorized shares of the Company's common stock or preferred stock, or to the par value per share of common stock due to the reverse stock split. All per share amounts and common shares outstanding for all periods presented in the unaudited consolidated financial statements have been adjusted retroactively to reflect the Company's one-for-fifty reverse stock split.

After giving effect to the reverse stock split, the total number of shares of all classes of capital stock that the Company was authorized to issue was 310,000,000 shares, 300,000,000 shares of Common Stock, having a par value of $0.001, and 10,000,000 shares of Preferred Stock, having a par value of $0.001.
v3.23.2
DISCONTINUED OPERATIONS
 6 Months Ended
Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS
As discussed in Note 1 – Nature of Operations – the exit from our pharmacy services business was substantially completed as of March 31, 2023. The pharmacy services business previously was a reportable segment and the exit represents a strategic shift in the Company going forward. Accordingly, with the sale or disposition of its retail pharmacy assets and exit from the pharmacy services business, this transaction meets the accounting requirements for reporting as discontinued operations under ASC 205-20-50 for all periods presented.

The following table summarizes the major income and expense line items from discontinued operations as reported in the condensed consolidated statements of operations and comprehensive loss:

Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2023202220232022
Revenue:
Pharmacy revenue$— $10,641 $3,834 $19,490 
Total revenue— 10,641 3,834 19,490 
Cost of products sold and services:
Pharmacy cost of products sold— 9,931 3,581 18,412 
Total cost of products sold and services— 9,931 3,581 18,412 
Operating expense:
Pharmacy operations157 3,450 1,883 7,170 
General and administrative141 1,242 711 2,560 
Selling and marketing— 2,253 845 4,457 
Research and development— 63 — 299 
Total operating expense298 7,008 3,439 14,486 
Operating loss(298)(6,298)(3,186)(13,408)
Loss from sale and disposition of net assets, and reorganization expenses, net— — (1,885)— 
Interest expense3 (3)4 (6)
Loss from discontinued operations$(295)$(6,301)$(5,067)$(13,414)

Cash used by operating activities by the pharmacy services business totaled $987 thousand and $14.4 million for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash provided by (used in) investing activities from the pharmacy services business totaled $212 thousand and $(428) thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash used in financing activities from the pharmacy services business totaled $47 thousand and $41 thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. Depreciation and amortization expense of the pharmacy services business totaled $895 thousand and $673 thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. The condensed consolidated statements of cash flows included $319 thousand loss on disposal of net assets from discontinued operations, which comprised of losses related to net realizable value adjustments to right of use assets related to leases and prepaid assets, and abandonment of certain property, plant, and equipment related to our discontinued operations.
The following table summarizes the major classes of assets and liabilities of the retail pharmacy business as reported on the condensed consolidated balance sheets:
(in thousands)June 30, 2023December 31, 2022
Carrying amounts of major classed of assets included as part of discontinued operations:
Accounts receivable, net$946 $1,805 
Prepaid expenses and other current assets— 94 
Inventories— 2,943 
Total current assets from discontinued operations$946 $4,842 
Intangible assets, net$— $14 
Property plant and equipment, net— 1,194 
Right-of-use assets622 1,461 
Other assets107 168 
Total long-term assets from discontinued operations$729 $2,837 
Total long-term assets from discontinued operations
Accounts payable$162 $857 
Accrued liabilities954 641 
Accrued payroll and benefits81 834 
Current portion of lease obligations315 462 
Total current liabilities from discontinued operations$1,512 $2,794 
Long-term portion of lease obligations$651 $1,128 
Total long-term liabilities from discontinued operations$651 $1,128 
v3.23.2
STOCKHOLDERS' EQUITY
 6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
STOCKHOLDERS' EQUITY WARRANTS
The Company effected the Reverse Stock Split on July 31, 2023, pursuant to which every 50 shares of the Company’s common stock was combined into one share. The number of underlying shares and the exercise price of each of the Company’s warrants were proportionately adjusted to give effect to the Reverse Stock Split. The Reverse Stock Split had no effect on the accounting for the Company’s warrants.

2022 Warrants
On March 30, 2022, the Company entered into a Securities Purchase Agreement with certain investors. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell in a private placement, or the 2022 Private Placement, up to 942 thousand shares of the Company’s common stock and warrants, or the 2022 Warrants, to purchase up to 470 thousand shares of common stock. The securities were sold at two closings at a price per share of $50.13.

At the first closing on April 4, 2022, the Company sold 75.2 thousand shares of common stock and 2022 Warrants to purchase up to 376 thousand shares of common stock, for gross proceeds of $40.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on April 4, 2022 had a fair value of $9.2 million, a 5 year term and a per share exercise price of $62.50. A second and final closing occurred on July 1, 2022, at which the Company sold an additional 188 thousand shares of common stock and 2022 Warrants to purchase up to 94.0 thousand shares of common stock, for gross proceeds of $10.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on July 1, 2022 had a fair value of $4.5 million, a 5 year term and a per share exercise price of $62.50.

None of the 2022 Warrants have been exercised or expired as of June 30, 2023 and December 31, 2022. The 2022 Warrants meet equity classification requirements and therefore are classified in our stockholders’ equity.

2023 SVB Warrants
On February 10, 2023, as part of the First Amendment to the Loan and Security Agreement with Silicon Valley Bank ("SVB") (see Note 8), the Company issued warrants, or SVB Warrants, to purchase up to an aggregate of 4 thousand shares of common stock at a per share exercise price of $16.37, with an expiration date of February 10, 2035. The number of shares and the exercise price were subject to adjustment, or the Special Adjustment for Warrant Shares, upon the occurrence of the last closing of the Company’s next equity financing, as set forth in the SVB Warrants.

On March 9, 2023, the Company entered into the 2023 Purchase Agreement, with certain institutional investors, pursuant to which the Company sold securities in a private placement at two closings that constituted the Company’s next equity financing within the meaning of the SVB Warrants. The first closing occurred on March 13, 2023 and the second closing occurred on June 16, 2023. On June 16, 2023, pursuant the Special Adjustment for Warrant Shares, the number of shares of common stock underlying the SVB Warrants increased to 5.4 thousand and the per share exercise price decreased to $10.25.

Upon the grant date, February 10, 2023, the fair value of the SVB Warrants was approximately $57 thousand measured using the Black-Scholes option pricing model. The SVB Warrants met equity classification requirement under ASC 815 - Derivative and Hedging, specifically
due to the warrants having a limit on the number of shares the Company is required to deliver upon exercise and the warrant not including cash-settled top-off or make-whole provisions, as well as, other conditions. As such, the SVB Warrants met the equity classification requirements and are classified in the Company's stockholders' equity. None of the SVB Warrants have been exercised or expired as of June 30, 2023.

The key input assumptions utilized in the valuation of the SVB Warrants were as follows:
Grant date
Market price$16.00
Exercise price$16.37
Term (Years)12
Volatility85%
Risk Free Rate3.68%

2023 Pre-Funded and Series A Warrants
As noted above, on March 9, 2023, the Company entered into the 2023 Purchase Agreement with certain investors. Pursuant to the 2023 Purchase Agreement, the Company agreed to issue Pre-Funded Warrants and Series A Warrants. On March 13, 2023, at the first closing of the offering, the Company sold at a price of $16.06 per underlying share, Pre-Funded Warrants to purchase up to 996.3 thousand shares of common stock at an exercise price of $0.05 per share for total gross proceeds of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from the offering to fund costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. The number of Pre-Funded Warrants exercisable by investors was limited to 19.99% of the Company’s common stock outstanding immediately prior to the offering pursuant to a listing rule of The Nasdaq Stock Market, which required that the Company obtain stockholder approval of the issuance of shares above this 19.99% cap. The Pre-Funded Warrants were classified as a liability at issuance due to the need for the Company to obtain stockholder approval to settle the instruments in shares.

On March 9, 2023, the Company also agreed to issue Series A Warrants to purchase up to 996.3 thousand shares of common stock with an exercise price of $19.27 per share, which was conditional upon the Company obtaining stockholder approval of the issuance. The Series A Warrants were also classified as a liability as the Company had an irrevocable obligation to obtain stockholder approval of the issuance of the Series A Warrant, and as such did not have sufficient shares to settle the obligation and consequently failed the equity classification requirements pending shareholder approval.

On June 14, 2023, at its annual stockholders’ meeting, the Company obtained the requisite stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company issued the Series A Warrants on June 16, 2023.

Upon grant, March 13, 2023, the fair value of the Pre-Funded Warrants and Series A Warrants was $15.9 million and $10.5 million, respectively. The Company recorded the $10.4 million difference between the offering proceeds and grant date fair value as a loss on issuance of warrants in the statement of operations and comprehensive loss. Subsequent to its grant date fair value measurement, and through June 14, 2023, the Company remeasured the warrants at fair value and recognized a gain from change in fair value of warrants on the statement of operations and comprehensive loss. As of June 14, 2023, the fair value of Pre-Funded Warrants and Series A Warrants was $14.9 million and $9.3 million, respectively. For the three and six months ended June 30, 2023, the Company recognized a loss of $0.9 million and gain of $2.1 million in fair value remeasurement of the Pre-Funded Warrants and Series A Warrants, respectively.

Subsequent to the remeasurement of the Pre-Funded Warrants and Series A Warrants, the Company reassessed the liability classification of these warrants due to the Company obtaining on June 14, 2023, stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company determined that the Pre-Funded Warrants and Series A Warrants met the equity classification requirements, and the warrants were re-classified from liability to equity as of June 14, 2023.

The fair values of the Pre-Funded Warrants and Series A Warrants were measured using the Black-Scholes option pricing model. As of the grant date and June 14, 2023, the key input assumptions utilized in the valuation of the Pre-funded Warrants were as follows:
Grant dateJune 14, 2023
Market price$16.00$15.00
Exercise price$0.05$0.05
Term (Years)*IDFIDF
Volatility85%82%
Risk Free Rate3.70%3.90%
*Warrant is outstanding until fully exercised; as such, the term was measured as indefinite.

The key input assumptions utilized in the valuation of the Series A Warrants were as follows:
Grant dateJune 14, 2023
Market price$16.00$15.00
Exercise price$19.27$19.27
Term (Years)54.7
Volatility85%82%
Risk Free Rate3.68%4.10%
STOCKHOLDERS' EQUITY
Reverse Stock Split
On June 14, 2023, the stockholders of the Company approved a one-for-fifty reverse stock split of its outstanding shares of common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on July 31, 2023 (the “Effective Time”). At the Effective Time, every fifty issued and outstanding shares of the Company’s common stock were converted into one share of the Company’s common stock.

The reverse split affected all the stockholders uniformly and did not affect any stockholder’s percentage ownership interests in the Company or proportionate voting power. Each common stockholder held the same percentage of the outstanding common stock immediately following the reverse split as that stockholder did immediately before the reverse split, except for minor adjustments as a result of the treatment of fractional shares.

No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). As a result, the number of common shares outstanding was reduced from 80,693,517 immediately before the Effective Time to 1,613,870.

There was no change in the number of authorized shares of the Company's common stock or preferred stock, or to the par value per share of common stock due to the reverse stock split. All per share amounts and common shares outstanding for all periods presented in the unaudited consolidated financial statements have been adjusted retroactively to reflect the Company's one-for-fifty reverse stock split.

After giving effect to the reverse stock split, the total number of shares of all classes of capital stock that the Company was authorized to issue was 310,000,000 shares, 300,000,000 shares of Common Stock, having a par value of $0.001, and 10,000,000 shares of Preferred Stock, having a par value of $0.001.
v3.23.2
SUBSEQUENT EVENTS
 6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
Reverse Stock Split
On June 14, 2023, the stockholders of the Company approved resolutions to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, par value of $0.001 per share, at a specific ratio within a range of 1-for-30 to 1-for-80, with the specific ratio to be fixed within this range to be determined by the Board of Directors in its sole discretion without further loss per share approval. On July 14, 2023, the Board of Directors approved a ratio of 1-for-50, such that every 50 shares of the Company’s common stock were combined into one share of its common stock at 5:00 p.m. Eastern Time on July 31, 2023.
v3.23.2
BASIS OF PRESENTATION (Policies)
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information, and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements.
The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. The Company's critical accounting policies are those that are both most important to its financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company is not aware of any events or circumstances which would require update to its estimates or judgements as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2022 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or SEC, on April 14, 2023 and retrospectively revised and recast for discontinued operation presentation in the Company's Current Report on Form 8-K filed with the SEC on June 29, 2023.
Principles of Consolidation
Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

As noted in Note 1, the Company substantially completed its exit from the pharmacy services business as of March 31, 2023. As a result, the Company has reported the operating results of its pharmacy services business in the loss from discontinued operations line in the condensed consolidated statements of operations for all periods presented. In addition, related assets and liabilities were reported as assets of discontinued operations and liabilities of discontinued operations in the condensed consolidated balance sheets for all periods presented. Unless otherwise noted, the discussion within these notes to the condensed consolidated financial statements relates to continuing operations comprised of the pharmacy technology business. See Note 13 for additional information on discontinued operations.
Recently Issued Accounting Standards Not Yet Adopted and Recently Adopted Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions
In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, or ASU 2022-03. The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements.

There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated financial statements through the reporting date.

Recently Adopted Accounting Standards

Measurement of Credit Losses on Financial Statements
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments”, or ASU 2016-13, supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, or ASU 2018-19. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, and for fiscal years beginning after December 15, 2022 for all other public business entities and private companies, with early adoption permitted. Effective January 1, 2023, the Company adopted ASU No. 2016-13. The impact of adoption of ASU 2016-13 was not material to its consolidated financial statements.
v3.23.2
LOSS PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Warrants Included in Earnings per Share
The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding. After these warrants are exercised, the related issued and outstanding common shares are included in weighted average shares outstanding:

SharesIssuance DateExercise Date
386November 18, 2020Outstanding
996,264March 9, 2023Outstanding
v3.23.2
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Changes in the Fair Value of the Pre-funded and Series a Warrants
The following table presents the changes in the fair value of the Pre-Funded and Series A Warrants during the six months ended June 30, 2023:
(in thousands)Pre-Funded Warrant
Liability		Series-A Warrant
Liability		Loss on Issuance of WarrantsGain from Change in Fair Value of Warrant Liabilities
Measurement at March 13, 2023$15,940 $10,484 $(10,424)$— 
Change in fair value$(996)$(1,153)— 2,149 
Measurement at June 14, 2023$14,944 $9,331 
v3.23.2
BALANCE SHEET AND OTHER INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Inventory The following table presents detail of inventory balances:
June 30,December 31,
(in thousands)20232022
Inventory:
MedCenter hardware$7,924 $8,154 
Spare parts2,141 663 
Total inventory$10,065 $8,817 
Schedule of Prepaid Expenses and Other Current Assets
The following table presents prepaid expenses and other current assets balances:
June 30,December 31,
(in thousands)20232022
Prepaid expenses and other current assets:
Prepaid MedCenter inventory$— $1,359 
Prepaid insurance467 921 
Other244 289 
Total prepaid expenses and other current assets$711 $2,569 
Schedule of Property, Plant and Equipment and Useful Lives
The following tables present property, plant and equipment balances:
Estimated useful livesJune 30,December 31,
(in thousands)20232022
Property, plant and equipment:
MedCenter equipment
8 years
$1,530 $1,357 
IT equipment
1 - 3 years
2,002 1,908 
Leasehold improvementslesser of useful life or term of lease316 316 
General plant and equipment
5 - 8 years
376 373 
Office furniture and equipment
5 - 8 years
332 217 
Vehicles
5 years
36 36 
Construction-in-process5 5 
Total historical cost4,597 4,212 
Accumulated depreciation(3,865)(3,774)
Total property, plant and equipment, net$732 $438 
Schedule of Intangible Assets
The following table presents intangible asset balances:
June 30,December 31,
(in thousands)20232022
Gross intangible assets:
Intellectual property$3,857 $3,857 
Software2,337 2,200 
Website and mobile application534 534 
Other123 — 
Total intangible assets6,851 6,591 
Accumulated amortization:
Intellectual property(3,857)(3,857)
Software(1,801)(1,749)
Website and mobile application(534)(534)
Other(2)— 
Total accumulated amortization(6,194)(6,140)
Total intangible assets, net$657 $451 
Schedule of Lease Assets and Liabilities
Balance sheet amounts for lease assets and leases liabilities are as follows:
June 30,December 31,
(in thousands)20232022
Lease Assets:
Operating$499$620
Finance2024
Total lease assets$701$624
Lease liabilities:
Operating:
Current$173 $241 
Long-term382 441 
Finance:
Current35 5 
Long-term168 — 
Total lease liabilities$758 $687 
The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows:
June 30,December 31,
20232022
Finance leases:
Weighted-average remaining lease term (years)4.50.5
Weighted-average discount rate11.5 %6.0 %
Operating leases:
Weighted-average remaining lease term (years)3.43.6
Weighted-average discount rate6.1 %7.3 %
Schedule of Maturities of Operating Lease Liabilities
Maturities of operating leases liabilities are as follows:
(in thousands)
Remaining period in 2023$135 
2024148 
2025152 
2026157 
202737 
Total operating lease payments629 
Less: present value discount(74)
Total operating leases$555 
Schedule of Maturities of Finance Lease Liabilities
Maturities of finance lease liabilities are as follows:
(in thousands)
Remaining period in 2023$29 
202458 
202558 
202658 
202758 
Total finance lease payments261 
Less: imputed interest(58)
Total finance leases$203 
v3.23.2
DEBT (Tables)
 6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Debt
The following table presents debt balances:
June 30,December 31,
(in thousands)20232022
Term loan$2,002 $5,182 
Term loan issuance costs, net(496)(384)
Long-term debt, net$1,506 $4,798 
Schedule of Maturities of Debt Liabilities
Maturities of debt liabilities are as follows:
(in thousands)
Remaining period in 2023$— 
2024668 
20251,000 
2026334 
Total debt$2,002 
v3.23.2
SHARE-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation Expense
The following table presents the Company's expense related to share-based compensation, in thousands:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Share-based compensation $381 $612 $999 $1,176 
Schedule of Outstanding Option Awards Activity
The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2023:
(in thousands, except for share and per share amounts)Number of AwardsWeighted Average Exercise PriceWeighted Average Fair ValueWeighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value
Outstanding, at December 31, 202287,995 $94.64 $57.26 $— 
Granted43,637 15.25 11.66 1 
Exercised/Released— — — — 
Expired(62)622.69 372.66 — 
Forfeited(28,362)95.49 53.27 — 
Outstanding, end of period, at June 30, 2023103,208 $60.66 $39.03 9.11$— 
Vested and exercisable, at June 30, 2023 37,186 107.53 66.14 8.18— 
Vested and unvested exercisable, at June 30, 202337,186 107.53 66.14 8.18— 
Vested and expected to vest, at June 30, 2023100,542 61.91 39.79 9.09— 
Schedule of Outstanding RSU Awards Activity The following table present outstanding RSU awards activity during the six months ended June 30, 2023:
Number of AwardsWeighted Average Exercise PriceWeighted Average Grant Date Fair ValueWeighted Average Remaining Contractual Life (Years)
Unvested outstanding, at December 31, 202247,531 $— $65.30 — 
Granted— $— $— — 
Exercised/Released(9,702)$15.84 $77.02 — 
Cancelled/Forfeited(18,983)$— $62.67 — 
Expired— $— $— — 
Unvested outstanding, at June 30, 202318,846 $— $61.99 14.29
Vested outstanding shares at June 30, 2023— $— $— — 
v3.23.2
WARRANTS (Tables)
 6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Schedule of Assumptions in Valuation of Awards Other than Options Granted and Warrant Issued
The key input assumptions utilized in the valuation of the SVB Warrants were as follows:
Grant date
Market price$16.00
Exercise price$16.37
Term (Years)12
Volatility85%
Risk Free Rate3.68%
As of the grant date and June 14, 2023, the key input assumptions utilized in the valuation of the Pre-funded Warrants were as follows:
Grant dateJune 14, 2023
Market price$16.00$15.00
Exercise price$0.05$0.05
Term (Years)*IDFIDF
Volatility85%82%
Risk Free Rate3.70%3.90%
*Warrant is outstanding until fully exercised; as such, the term was measured as indefinite.

The key input assumptions utilized in the valuation of the Series A Warrants were as follows:
Grant dateJune 14, 2023
Market price$16.00$15.00
Exercise price$19.27$19.27
Term (Years)54.7
Volatility85%82%
Risk Free Rate3.68%4.10%
v3.23.2
DISCONTINUED OPERATIONS (Tables)
 6 Months Ended
Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Income, Assets and Liabilities from Discontinued Operations
The following table summarizes the major income and expense line items from discontinued operations as reported in the condensed consolidated statements of operations and comprehensive loss:

Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2023202220232022
Revenue:
Pharmacy revenue$— $10,641 $3,834 $19,490 
Total revenue— 10,641 3,834 19,490 
Cost of products sold and services:
Pharmacy cost of products sold— 9,931 3,581 18,412 
Total cost of products sold and services— 9,931 3,581 18,412 
Operating expense:
Pharmacy operations157 3,450 1,883 7,170 
General and administrative141 1,242 711 2,560 
Selling and marketing— 2,253 845 4,457 
Research and development— 63 — 299 
Total operating expense298 7,008 3,439 14,486 
Operating loss(298)(6,298)(3,186)(13,408)
Loss from sale and disposition of net assets, and reorganization expenses, net— — (1,885)— 
Interest expense3 (3)4 (6)
Loss from discontinued operations$(295)$(6,301)$(5,067)$(13,414)
The following table summarizes the major classes of assets and liabilities of the retail pharmacy business as reported on the condensed consolidated balance sheets:
(in thousands)June 30, 2023December 31, 2022
Carrying amounts of major classed of assets included as part of discontinued operations:
Accounts receivable, net$946 $1,805 
Prepaid expenses and other current assets— 94 
Inventories— 2,943 
Total current assets from discontinued operations$946 $4,842 
Intangible assets, net$— $14 
Property plant and equipment, net— 1,194 
Right-of-use assets622 1,461 
Other assets107 168 
Total long-term assets from discontinued operations$729 $2,837 
Total long-term assets from discontinued operations
Accounts payable$162 $857 
Accrued liabilities954 641 
Accrued payroll and benefits81 834 
Current portion of lease obligations315 462 
Total current liabilities from discontinued operations$1,512 $2,794 
Long-term portion of lease obligations$651 $1,128 
Total long-term liabilities from discontinued operations$651 $1,128 
v3.23.2
NATURE OF OPERATIONS (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jul. 31, 2023
$ / shares
Jul. 14, 2023
Jun. 14, 2023
$ / shares
Feb. 09, 2023
USD ($)
Jan. 18, 2023
Dec. 31, 2022
USD ($)
$ / shares
Jun. 30, 2023
USD ($)
$ / shares
Business Acquisition, Equity Interests Issued or Issuable [Line Items]              
Reduction of full-time employees, percentage         75.00%    
Sale price       $ 2,900      
Fees       100      
Holdback       $ 200      
Inventories           $ 8,817 $ 10,065
Common shares, par value (in USD per share) | $ / shares     $ 0.001     $ 0.001 [1] $ 0.001 [1]
Stock split, conversion ratio     0.0200        
Subsequent Event              
Business Acquisition, Equity Interests Issued or Issuable [Line Items]              
Common shares, par value (in USD per share) | $ / shares $ 0.001            
Stock split, conversion ratio 0.0200 0.0200          
Minimum              
Business Acquisition, Equity Interests Issued or Issuable [Line Items]              
Stock split, conversion ratio     0.0333        
Maximum              
Business Acquisition, Equity Interests Issued or Issuable [Line Items]              
Stock split, conversion ratio     0.0125        
Pharmacy Services Business | Revenue | Product Concentration Risk              
Business Acquisition, Equity Interests Issued or Issuable [Line Items]              
Concentration risk, percentage           97.00%  
Inventory From SpotRx Pharmacies              
Business Acquisition, Equity Interests Issued or Issuable [Line Items]              
Inventories           $ 3,000  
Inventory From SpotRx Pharmacies | Assets, Total | Product Concentration Risk              
Business Acquisition, Equity Interests Issued or Issuable [Line Items]              
Concentration risk, percentage           9.00%  
[1] Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
v3.23.2
LIQUIDITY (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Mar. 09, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 16, 2023
Mar. 13, 2023
Dec. 31, 2022
Mar. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]                
Proceeds from issuance of warrants in private placement   $ 15,999 $ 37,201          
Cash and cash equivalents, including restricted cash   15,035 29,878     $ 12,120   $ 20,089
Accumulated deficit   262,827       $ 239,706    
Net cash used in operating activities   $ 9,589 $ 25,714          
Pre-Funded Warrant Liability                
Debt Instrument [Line Items]                
Proceeds from issuance of warrants in private placement $ 16,000              
Number of shares called by warrants (in shares) 996,300              
Exercise price of warrants issued (in USD per share) $ 0.05              
Series-A Warrant Liability                
Debt Instrument [Line Items]                
Number of shares called by warrants (in shares) 996,300              
Exercise price of warrants issued (in USD per share) $ 19.27              
Private Placement                
Debt Instrument [Line Items]                
Proceeds from issuance of warrants in private placement $ 16,000              
Number of shares called by warrants (in shares)             470,000  
Private Placement | Pre-Funded Warrant Liability                
Debt Instrument [Line Items]                
Number of shares called by warrants (in shares)         49,813,198      
Exercise price of warrants issued (in USD per share)         $ 0.001      
Private Placement | Series-A Warrant Liability                
Debt Instrument [Line Items]                
Number of shares called by warrants (in shares)       49,813,198        
Exercise price of warrants issued (in USD per share)       $ 0.38544        
v3.23.2
LOSS PER SHARE - Warrants Included in Earnings per Share (Details)
 6 Months Ended
Jun. 30, 2023
shares
Warrants Issued November 18, 2020, Outstanding  
Common  
Warrants (in shares) 386
Warrants Issued March 9, 2023, Outstanding  
Common  
Warrants (in shares) 996,264
v3.23.2
LOSS PER SHARE - Narrative (Details) - shares
shares in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share [Abstract]    
Potentially dilutive option awards excluded from earnings per share calculation (in shares) 1,600 94
v3.23.2
FAIR VALUE MEASUREMENTS - Narrative (Details) - Fair Value, Recurring - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Class of Warrant or Right [Line Items]    
Assets, fair value disclosure $ 0 $ 0
Liabilities, fair value disclosure $ 0 $ 0
v3.23.2
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 13, 2023
Jun. 30, 2023
Jun. 14, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Fair Value of Warrant Liability [Roll Forward]            
Loss on issuance of warrants $ (10,424) $ 0   $ 0 $ (10,424) $ 0
(Loss) gain from change in fair value of warrant liabilities   896 $ 2,149 $ 0 (2,149) $ 0
Pre-Funded Warrant Liability            
Fair Value of Warrant Liability [Roll Forward]            
Loss on issuance of warrants   (900)     (900)  
Series-A Warrant Liability            
Fair Value of Warrant Liability [Roll Forward]            
Loss on issuance of warrants   $ 2,100     $ 2,100  
Fair Value, Recurring | Pre-Funded Warrant Liability | Warrant Liability            
Fair Value of Warrant Liability [Roll Forward]            
Measurement at March 13, 2023     15,940      
Change in fair value     (996)      
Measurement at June 14, 2023 15,940   14,944      
Fair Value, Recurring | Series-A Warrant Liability | Warrant Liability            
Fair Value of Warrant Liability [Roll Forward]            
Measurement at March 13, 2023     10,484      
Change in fair value     (1,153)      
Measurement at June 14, 2023 $ 10,484   $ 9,331      
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Inventory [Line Items]          
Restricted cash $ 676   $ 676   $ 676
Depreciation included in cost of sales 57 $ 57 90 $ 117  
Amortization of intangible assets     68 295  
Operating lease, expense 25 126 154 256  
Hardware and subscription revenue          
Inventory [Line Items]          
Inventory recognized as cost of sales 103 176 314 232  
Depreciation included in cost of sales 2 26 11 52  
Amortization of intangible assets $ 28 $ 20 $ 54 $ 22  
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
MedCenter hardware $ 7,924 $ 8,154
Spare parts 2,141 663
Total inventory $ 10,065 $ 8,817
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Prepaid MedCenter inventory $ 0 $ 1,359
Prepaid insurance 467 921
Other 244 289
Total prepaid expenses and other current assets $ 711 $ 2,569
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total historical cost $ 4,597 $ 4,212
Accumulated depreciation (3,865) (3,774)
Total property, plant and equipment, net $ 732 438
MedCenter equipment    
Property, Plant and Equipment [Line Items]    
Estimated useful lives 8 years  
Total historical cost $ 1,530 1,357
IT equipment    
Property, Plant and Equipment [Line Items]    
Total historical cost $ 2,002 1,908
IT equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated useful lives 1 year  
IT equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated useful lives 3 years  
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total historical cost $ 316 316
General plant and equipment    
Property, Plant and Equipment [Line Items]    
Total historical cost $ 376 373
General plant and equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated useful lives 5 years  
General plant and equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated useful lives 8 years  
Office furniture and equipment    
Property, Plant and Equipment [Line Items]    
Total historical cost $ 332 217
Office furniture and equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated useful lives 5 years  
Office furniture and equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated useful lives 8 years  
Vehicles    
Property, Plant and Equipment [Line Items]    
Estimated useful lives 5 years  
Total historical cost $ 36 36
Construction-in-process    
Property, Plant and Equipment [Line Items]    
Total historical cost $ 5 $ 5
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets $ 6,851 $ 6,591
Total accumulated amortization (6,194) (6,140)
Total intangible assets, net 657 451
Intellectual property    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 3,857 3,857
Total accumulated amortization (3,857) (3,857)
Software    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 2,337 2,200
Total accumulated amortization (1,801) (1,749)
Website and mobile application    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 534 534
Total accumulated amortization (534) (534)
Other    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 123 0
Total accumulated amortization $ (2) $ 0
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Leases, Balance Sheet Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Total lease assets Total lease assets
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Total lease assets Total lease assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Current portion of lease obligations Current portion of lease obligations
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Long-term portion of lease obligations Long-term portion of lease obligations
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Current portion of lease obligations Current portion of lease obligations
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Long-term portion of lease obligations Long-term portion of lease obligations
Assets    
Operating $ 499 $ 620
Finance 202 4
Total lease assets 701 624
Operating:    
Current 173 241
Long-term 382 441
Finance:    
Current 35 5
Long-term 168 0
Total lease liabilities $ 758 $ 687
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Additional Lease Information (Details)
Jun. 30, 2023
Dec. 31, 2022
Finance leases:    
Weighted-average remaining lease term (years) 4 years 6 months 6 months
Weighted-average discount rate 11.50% 6.00%
Operating leases:    
Weighted-average remaining lease term (years) 3 years 4 months 24 days 3 years 7 months 6 days
Weighted-average discount rate 6.10% 7.30%
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Leases, Operating Lease Liability Maturity (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Remaining period in 2023 $ 135
2024 148
2025 152
2026 157
2027 37
Total operating lease payments 629
Less: present value discount (74)
Total operating leases $ 555
v3.23.2
BALANCE SHEET AND OTHER INFORMATION - Leases, Finance Lease Liability Maturity (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Remaining period in 2023 $ 29
2024 58
2025 58
2026 58
2027 58
Total finance lease payments 261
Less: imputed interest (58)
Total finance leases $ 203
v3.23.2
DEBT - Schedule of Debt (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Term loan $ 2,002  
Long-term debt, net 1,506 $ 4,798
Term loan | Secured Debt    
Debt Instrument [Line Items]    
Term loan 2,002 5,182
Term loan issuance costs, net $ (496) $ (384)
v3.23.2
Debt - Schedule of Maturities of Debt Liabilities (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Debt Disclosure [Abstract]  
Remaining period in 2023 $ 0
2024 668
2025 1,000
2026 334
Total debt $ 2,002
v3.23.2
DEBT - Narrative (Details) - USD ($)
$ in Thousands
 6 Months Ended
Feb. 10, 2023
Jun. 30, 2023
Mar. 29, 2023
Dec. 31, 2022
Debt Instrument [Line Items]        
Payment of assets sale $ 3,400      
Final payment 400      
Prepayment $ 3,000      
Cash in bank accounts   $ 14,359   $ 11,444
SVB Warrants        
Debt Instrument [Line Items]        
Percent threshold of dollar value of total accounts held at financial institutions     50.00%  
Cash in bank accounts   9,700    
Other Financial Institution        
Debt Instrument [Line Items]        
Cash in bank accounts   $ 5,300    
Term loan | Secured Debt        
Debt Instrument [Line Items]        
Debt instrument, interest rate floor   7.25%    
Interest rate at end of period   12.25%    
Term loan | Secured Debt | Prime Rate        
Debt Instrument [Line Items]        
Variable interest rate spread   4.00%    
v3.23.2
SHARE-BASED COMPENSATION - Share Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]        
Share-based compensation $ 381 $ 612 $ 999 $ 1,176
v3.23.2
SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)
shares in Thousands, $ in Millions
 6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expense remaining to be recognized $ 1.5  
Weighted average recognition period (in years) 2 years  
2020 Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Aggregate shares of common stock available for grant (in shares) 93 46
2022 Inducement Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Aggregate shares of common stock available for grant (in shares) 22 4
Restricted Stock Units (RSUs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expense remaining to be recognized $ 0.9  
Weighted average recognition period (in years) 1 year 6 months  
v3.23.2
SHARE-BASED COMPENSATION - Option Activity (Details)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Number of Awards  
Outstanding awards at beginning of period (in shares) | shares 87,995
Granted (in shares) | shares 43,637
Exercised/released (in shares) | shares 0
Expired (in shares) | shares (62)
Forfeited (in shares) | shares (28,362)
Outstanding awards at end of period (in shares) | shares 103,208
Awards vested and exercisable (in shares) | shares 37,186
Awards vested and unvested exercisable (in shares) | shares 37,186
Awards vested and expected to vest (in shares) | shares 100,542
Weighted Average Exercise Price  
Outstanding awards at beginning of period (in USD per share) $ 94.64
Granted (in USD per share) 15.25
Exercised/released (in USD per share) 0
Expired (in USD per share) 622.69
Forfeited (in USD per share) 95.49
Outstanding at end of period (in USD per share) 60.66
Weighted average exercise price of awards vested and exercisable (in USD per share) 107.53
Weighted average exercise price of awards vested and unvested exercisable (in USD per share) 107.53
Weighted average exercise price of awards vested and expected to vest (in USD per share) 61.91
Weighted Average Fair Value  
Outstanding at beginning of period (in USD per share) 57.26
Granted (in USD per share) 11.66
Exercised/released (in USD per share) 0
Expired (in USD per share) 372.66
Forfeited (in USD per share) 53.27
Outstanding at end of period (in USD per share) 39.03
Weighted average fair value of awards vested and exercisable (in USD per share) 66.14
Weighted average fair value of awards vested and unvested exercisable (in USD per share) 66.14
Weighted average fair value of awards vested and expected to vest (in USD per share) $ 39.79
Weighted Average Remaining Contractual Life (Years)  
Outstanding, end of period 9 years 1 month 9 days
Vested and exercisable, end of the period 8 years 2 months 4 days
Vested and unvested exercisable, end of the period 8 years 2 months 4 days
Vested and expected to vest, end of the period 9 years 1 month 2 days
Aggregate Intrinsic Value  
Outstanding, at December 31, 2022 | $ $ 0
Granted | $ 1
Exercised/Released | $ 0
Expired | $ 0
Forfeited | $ 0
Outstanding, end of period, at June 30, 2023 | $ 0
Aggregate intrinsic value of awards vested and exercisable | $ 0
Aggregate intrinsic value of awards vested and unvested exercisable | $ 0
Aggregate intrinsic value of awards vested and expected to vest | $ $ 0
v3.23.2
SHARE-BASED COMPENSATION - RSU Activity (Details) - Restricted Stock Units (RSUs)
 6 Months Ended
Jun. 30, 2023
$ / shares
shares
Number of Awards  
Outstanding awards at beginning of period (in shares) | shares 47,531
Granted (in shares) | shares 0
Exercised/Released (in shares) | shares (9,702)
Cancelled/Forfeited (in shares) | shares (18,983)
Expired (in shares) | shares 0
Outstanding awards at end of period (in shares) | shares 18,846
Vested, outstanding shares (in shares) | shares 0
Weighted Average Exercise Price  
Unvested outstanding, beginning of period (in USD per share) $ 0
Granted (in USD per share) 0
Exercised/Released (in USD per share) 15.84
Cancelled/Forfeited (in USD per share) 0
Expired (in USD per share) 0
Unvested outstanding, end of period (in USD per share) 0
Vested, outstanding shares (in USD per share) 0
Weighted Average Fair Value  
Unvested outstanding, beginning of period (in USD per share) 65.30
Granted (in USD per share) 0
Exercised/Released (in USD per share) 77.02
Cancelled/Forfeited (in USD per share) 62.67
Expired (in USD per share) 0
Unvested outstanding, end of period (in USD per share) 61.99
Vested, outstanding shares (in USD per share) $ 0
Weighted Average Remaining Contractual Life (Years)  
Weighted average remaining contractual life 14 years 3 months 14 days
v3.23.2
WARRANTS - Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 14, 2023
Jun. 14, 2023
USD ($)
Mar. 13, 2023
USD ($)
$ / shares
shares
Mar. 09, 2023
USD ($)
$ / shares
shares
Jul. 01, 2022
USD ($)
$ / shares
shares
Apr. 04, 2022
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 16, 2023
$ / shares
shares
Feb. 10, 2023
USD ($)
$ / shares
shares
Mar. 30, 2022
closing
$ / shares
shares
Class of Warrant or Right [Line Items]                            
Stock split, conversion ratio     0.0200                      
Proceeds from issuance of warrants in private placement                   $ 15,999 $ 37,201      
Gain (loss) on issuance of warrants       $ (10,424)       $ 0 $ 0 (10,424) $ 0      
Private Placement                            
Class of Warrant or Right [Line Items]                            
Number of shares authorized to be sold (in shares) | shares                           942,000
Number of shares called by warrants (in shares) | shares                           470,000
Number of closings | closing                           2
Sale of stock (in USD per share) | $ / shares                           $ 50.13
Proceeds from issuance of warrants in private placement         $ 16,000                  
Warrants Issued April 2022 | Private Placement                            
Class of Warrant or Right [Line Items]                            
Number of shares called by warrants (in shares) | shares             376,000              
Number of shares sold or expected to be sold (in shares) | shares             75,200              
Gross proceeds from private placement             $ 40,000              
Fair value             $ 9,200              
Term of warrants (in years)             5 years              
Exercise price of warrants issued (in USD per share) | $ / shares             $ 62.50              
Warrants Issued July 2022 | Private Placement                            
Class of Warrant or Right [Line Items]                            
Number of shares called by warrants (in shares) | shares           94,000                
Number of shares sold or expected to be sold (in shares) | shares           188,000                
Gross proceeds from private placement           $ 10,000                
Fair value           $ 4,500                
Term of warrants (in years)           5 years                
Exercise price of warrants issued (in USD per share) | $ / shares           $ 62.50                
SVB Warrants                            
Class of Warrant or Right [Line Items]                            
Number of shares called by warrants (in shares) | shares                       5,400 4,000  
Fair value                         $ 57  
Exercise price of warrants issued (in USD per share) | $ / shares                       $ 10.25 $ 16.37  
Pre-Funded Warrant Liability                            
Class of Warrant or Right [Line Items]                            
Number of shares called by warrants (in shares) | shares         996,300                  
Fair value     $ 14,900 $ 15,900                    
Exercise price of warrants issued (in USD per share) | $ / shares         $ 0.05                  
Stock exercise price (in USD per share) | $ / shares         $ 16.06                  
Proceeds from issuance of warrants in private placement         $ 16,000                  
Percentage of common stock outstanding prior to offering         19.99%                  
Gain (loss) on issuance of warrants               (900)   (900)        
Pre-Funded Warrant Liability | Private Placement                            
Class of Warrant or Right [Line Items]                            
Number of shares called by warrants (in shares) | shares       49,813,198                    
Exercise price of warrants issued (in USD per share) | $ / shares       $ 0.001                    
Series-A Warrant Liability                            
Class of Warrant or Right [Line Items]                            
Number of shares called by warrants (in shares) | shares         996,300                  
Fair value     $ 9,300 $ 10,500                    
Exercise price of warrants issued (in USD per share) | $ / shares         $ 19.27                  
Gain (loss) on issuance of warrants               $ 2,100   $ 2,100        
Series-A Warrant Liability | Private Placement                            
Class of Warrant or Right [Line Items]                            
Number of shares called by warrants (in shares) | shares                       49,813,198    
Exercise price of warrants issued (in USD per share) | $ / shares                       $ 0.38544    
Subsequent Event                            
Class of Warrant or Right [Line Items]                            
Stock split, conversion ratio 0.0200 0.0200                        
v3.23.2
WARRANTS - Valuation of Warrants Issued (Details)
 6 Months Ended
Jun. 30, 2023
$ / shares
SVB Warrants  
Class of Warrant or Right [Line Items]  
Grant date, market price (in USD per share) $ 16.00
Grant date, exercise price (in USD per share) $ 16.37
Grant date, term (year) 12 years
Grant date, volatility 85.00%
Grant date, risk free rate 3.68%
Pre-Funded Warrant Liability  
Class of Warrant or Right [Line Items]  
Grant date, market price (in USD per share) $ 16.00
Grant date, exercise price (in USD per share) $ 0.05
Grant date, volatility 85.00%
Grant date, risk free rate 3.70%
Market price (in USD per share) $ 15.00
Exercise price (in USD per share) $ 0.05
Volatility 82.00%
Risk Free Rate 3.90%
Series-A Warrant Liability  
Class of Warrant or Right [Line Items]  
Grant date, market price (in USD per share) $ 16.00
Grant date, exercise price (in USD per share) $ 19.27
Grant date, term (year) 5 years
Grant date, volatility 85.00%
Grant date, risk free rate 3.68%
Market price (in USD per share) $ 15.00
Exercise price (in USD per share) $ 19.27
Term (Years) 4 years 8 months 12 days
Volatility 82.00%
Risk Free Rate 4.10%
v3.23.2
DISCONTINUED OPERATIONS - Schedule of Income from Discontinued Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expense:        
Loss from discontinued operations $ (295) $ (6,301) $ (5,067) $ (13,414)
Pharmacy Services Business | Discontinued Operations, Disposed of by Sale        
Revenue:        
Total revenue 0 10,641 3,834 19,490
Cost of products sold and services:        
Total cost of products sold and services 0 9,931 3,581 18,412
Operating expense:        
Pharmacy operations 157 3,450 1,883 7,170
General and administrative 141 1,242 711 2,560
Selling and marketing 0 2,253 845 4,457
Research and development 0 63 0 299
Total operating expense 298 7,008 3,439 14,486
Operating loss (298) (6,298) (3,186) (13,408)
Loss from sale and disposition of net assets, and reorganization expenses, net 0 0 (1,885) 0
Interest expense 3 (3) 4 (6)
Loss from discontinued operations $ (295) $ (6,301) $ (5,067) $ (13,414)
v3.23.2
DISCONTINUED OPERATIONS - Narrative (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Loss on disposal of net assets from discontinued operations $ 319 $ 0
Pharmacy Services Business | Discontinued Operations, Disposed of by Sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal group cash used in operating activities 987 14,400
Disposal group cash provided by (used in) investing activities 212 (428)
Disposal group cash used in financing activities 47 41
Disposal group depreciation and amortization $ 895 $ 673
v3.23.2
DISCONTINUED OPERATIONS - Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Carrying amounts of major classed of assets included as part of discontinued operations:    
Current assets from discontinued operations $ 946 $ 4,842
Long-term assets from discontinued operations 729 2,837
Total long-term assets from discontinued operations    
Total current liabilities from discontinued operations 1,512 2,794
Discontinued Operations, Disposed of by Sale | Pharmacy Services Business    
Carrying amounts of major classed of assets included as part of discontinued operations:    
Accounts receivable, net 946 1,805
Prepaid expenses and other current assets 0 94
Inventories 0 2,943
Current assets from discontinued operations 946 4,842
Intangible assets, net 0 14
Property plant and equipment, net 0 1,194
Right-of-use assets 622 1,461
Other assets 107 168
Long-term assets from discontinued operations 729 2,837
Total long-term assets from discontinued operations    
Accounts payable 162 857
Accrued liabilities 954 641
Accrued payroll and benefits 81 834
Current portion of lease obligations 315 462
Total current liabilities from discontinued operations 1,512 2,794
Long-term portion of lease obligations 651 1,128
Total long-term liabilities from discontinued operations $ 651 $ 1,128
v3.23.2
STOCKHOLDERS' EQUITY (Details)
Jul. 31, 2023
$ / shares
shares
Jul. 14, 2023
Jun. 14, 2023
$ / shares
Jul. 30, 2023
shares
Jun. 30, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Class of Stock [Line Items]            
Stock split, conversion ratio     0.0200      
Common shares, outstanding (in shares) [1]         1,613,870 1,603,394
Common shares, authorized (in shares) [1]         300,000,000 300,000,000
Common shares, par value (in USD per share) | $ / shares     $ 0.001   $ 0.001 [1] $ 0.001 [1]
Subsequent Event            
Class of Stock [Line Items]            
Stock split, conversion ratio 0.0200 0.0200        
Common shares, outstanding (in shares) 1,613,870     80,693,517    
Capital stock, authorized (in shares) 310,000,000          
Common shares, authorized (in shares) 300,000,000          
Common shares, par value (in USD per share) | $ / shares $ 0.001          
Preferred stock, authorized (in shares) 10,000,000          
Preferred stock, par value (in USD per share) | $ / shares $ 0.001          
[1] Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
v3.23.2
SUBSEQUENT EVENTS (Details)
Jul. 31, 2023
$ / shares
Jul. 14, 2023
Jun. 14, 2023
$ / shares
Jun. 30, 2023
$ / shares
 [1]
Dec. 31, 2022
$ / shares
 [1]
Subsequent Event [Line Items]          
Common shares, par value (in USD per share)     $ 0.001 $ 0.001 $ 0.001
Stock split, conversion ratio     0.0200    
Subsequent Event          
Subsequent Event [Line Items]          
Common shares, par value (in USD per share) $ 0.001        
Stock split, conversion ratio 0.0200 0.0200      
Minimum          
Subsequent Event [Line Items]          
Stock split, conversion ratio     0.0333    
Maximum          
Subsequent Event [Line Items]          
Stock split, conversion ratio     0.0125    
[1] Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
MedAvail (NASDAQ:MDVL)
過去 株価チャート
から 10 2024 まで 11 2024 MedAvailのチャートをもっと見るにはこちらをクリック
MedAvail (NASDAQ:MDVL)
過去 株価チャート
から 11 2023 まで 11 2024 MedAvailのチャートをもっと見るにはこちらをクリック